Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same

Information

  • Patent Grant
  • 9713652
  • Patent Number
    9,713,652
  • Date Filed
    Monday, August 26, 2013
    10 years ago
  • Date Issued
    Tuesday, July 25, 2017
    6 years ago
Abstract
Provided according to some embodiments of the invention are methods of forming co-condensed silica particles. In some embodiments, the methods include reacting a thiol-containing silane and a backbone alkoxysilane in a reaction solution that comprises water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles include a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix; and reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized co-condensed silica particles. In some embodiments, provided are S-nitrosothiol-functionalized co-condensed silica particles.
Description
FIELD OF THE INVENTION

The present invention relates to nitric oxide-releasing particles. More particularly, the present application relates to S-nitrosothiol-modified silica particles.


BACKGROUND OF THE INVENTION

Since the discovery of the physiological roles of nitric oxide (NO), much research has focused on the synthesis of NO-releasing materials/vehicles to elicit NO's characteristics as an antimicrobial agent, mediator of wound repair, or angiogenic cofactor. S-Nitrosothiols (RSNOs) are one class of endogenous NO donor believed to store/transport the majority of the body's natural reservoir of NO. As such, a large body of work has utilized low molecular weight RSNOs (e.g., S-nitroso-glutathione (GSNO), S-nitroso-N-acetylcysteine (SNAC), and S-nitroso-N-acetyl-penicillamine (SNAP)) as donors to spontaneously release NO. Although promising, the clinical application of low molecular weight NO donors has been slow due to both lack of tissue specific targeting and uncontrollable NO release kinetics. To address such shortcomings, NO donor precursors have been conjugated to larger scaffolds (e.g., proteins, dendrimers, and nanoparticles), thus enabling high NO storage per delivery vehicle and release profiles similar to their small molecule analogues.


Silica particles are among the most widely employed macromolecular scaffolds for biomedical applications due to facile synthetic strategies and minimal cytotoxicity. Previously, the surface of fumed silica particles (7-10 nm diameter) have been grafted with SNAP, SNAC, and S-nitrosocysteine (CysNO) to create S-nitrosothiol-modified silica particles. However, the NO storage was limited to 0.021-0.138 μmol mg−1 because the thiol functionalization was restricted to the exterior of the particle. Additionally, these systems are not able to tune particle size to fit a therapeutic system of interest. Alternatively, the hydrolysis and co-condensation of organosilane and tetraalkoxysilane precursors via sol-gel chemistry may represent a method for preparing a silica network with a higher concentration of organic functionalites. Indeed, the Stöber process (sol-gel chemistry with an alcohol solvent and an ammonia catalyst) has proven effective for synthesizing N-diazeniumdiolate-modified silica particles of diverse size and NO storage capacity. See, for example, U.S. Publication No. 2009/0214618 (Schoenfisch et al.), which is herein incorporated by reference in its entirety. The advantage of the Stöber method over surface grafting is that the co-condensation provides uniform incorporation of the organic (i.e., NO donor) functionality throughout the resulting silica network as opposed to restricted functionalization at the surface alone. As a result, such particles may exhibit significantly increased NO storage.


SUMMARY OF THE INVENTION

A first aspect of the present invention comprises a method of forming S-nitrosothiol-functionalized co-condensed silica particles comprising:

    • reacting a thiol-containing silane and a backbone alkoxysilane in a sol precursor solution that comprises water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles comprise a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix; and
    • reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized co-condensed silica particles.


A second aspect of the present invention comprises S-nitrosothiol-functionalized monodisperse co-condensed silica particles having an average particle diameter in a range of about 10 nm to about 100 μm.


A further aspect of the present invention comprises S-nitrosothiol-functionalized co-condensed silica particles having an NO storage in a range of about 0.01 μmol to about 10 μmol NO per mg particle.


Another aspect of the present invention comprises a S-nitrosothiol-functionalized co-condensed silica particle comprising tertiary nitrosothiol functional groups.


A further aspect of the present invention comprises a compound having the following structure:




embedded image



wherein R, R′ and R″ are each independently alkyl and n is 0 in a range of 0 to 10.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate certain embodiment(s) of the invention.



FIG. 1 provides a scheme for the synthesis of N-acetylpenicillamine propyltrimethoxysilane (NAPTMS).



FIG. 2 provides an 1H NMR spectrum of the NAPTMS compound.



FIG. 3 shows a solid-state cross polarization/magic angle spinning (CP/MAS) 29Si NMR spectra of silica synthesized with (A) 0, (B) 25, (C) 40, (D) 60, (E) 75, and (F) 85 mol % MPTMS (balance TMOS). The Q and T bands have been designated.



FIG. 4 shows the scanning electron micrographs of (A) 25, (B) 40, (C) 60, (D) 75 and (E) 85 mol % MPTMS (balance TMOS) and (F) 75 and (G) 85 mol % MPTMS (balance TEOS) particles synthesized with 16.0 M water, 5.5 M ammonia, and 0.1 M silane.



FIG. 5 shows the scanning electron micrographs of (A) 25, (B) 40, (C) 60, (D) 75 and (E) 85 mol % MPTMS (balance TMOS) and (F) 75 and (G) 85 mol % MPTMS (balance TEOS) particles synthesized via a semi-batch process with a silane feed rate of 0.5 nit min−1.



FIG. 6 shows the scanning electron micrographs of 75 mol % MPTMS (balance TEOS) synthesized with (A) 47.0, (B) 42.0, (C) 40.6, (D) 36.5, (E) 32.5, and (F) 24.9 M water.



FIG. 7 shows the scanning electron micrographs of (A-B) 25, (C-D) 40, (E-F) 60, (G-H) 75, and (1-J) 85 mol % MPTMS (balance TMOS) and (K-L) 85 mol % MPTMS (balance TEOS) particles synthesized with (A, C, E, F, G, I, K) 32.5 and (B, D, F, H, J, L) 24.9 M water.



FIG. 8 shows a schematic for the S-nitrosothiol decomposition pathways.



FIG. 9 shows the nitric oxide release from RSNO-modified 75 mol % MPTMS (balance TEOS) particles in the presence of (A) 0 (-), 60 (--), 100 (• • •), and 200 (-•) W irradiation at 0° C. and (B) 0 (-), 10 (--), and 25 (• • •) μM CuBr2/PBS solution at 0° C. Note: 0 μM CuBr2 is 500 μM DTPA (pH 7.4 PBS). The inset of A provides an enlarged view of NO release profile without irradiation.



FIG. 10 shows SEM images of tertiary thiol-functionalized co-condensed silica particles according to some embodiments of the invention prior to sonication.



FIG. 11 shows SEM images of tertiary thiol-functionalized co-condensed silica particles according to some embodiments of the invention after 30 minutes sonication followed by nitrosation.



FIG. 12 shows SEM images of tertiary thiol-functionalized co-condensed silica particles according to some embodiments of the invention after 60 minutes sonication followed by nitrosation.





DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

The foregoing and other aspects of the present invention will now be described in more detail with respect to the description and methodologies provided herein. It should be appreciated that the invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.


The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the embodiments of the invention and the appended claims, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Also, as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items. Furthermore, the term “about,” as used herein when referring to a measurable value such as an amount of a compound, dose, time, temperature, and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. Unless otherwise defined, all terms, including technical and scientific terms used in the description, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.


All patents, patent applications and publications referred to herein are incorporated by reference in their entirety. In the event of conflicting terminology, the present specification is controlling.


The embodiments described in one aspect of the present invention are not limited to the aspect described. The embodiments may also be applied to a different aspect of the invention as long as the embodiments do not prevent these aspects of the invention from operating for its intended purpose.


Chemical Definitions


As used herein the term “alkyl” refers to C1-20 inclusive, linear (i.e., “straight-chain”), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl)hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups. “Branched” refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. Exemplary branched alkyl groups include, but are not limited to, isopropyl, isobutyl, tert-butyl. “Lower alkyl” refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C1-8 alkyl), e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. “Higher alkyl” refers to an alkyl group having about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, “alkyl” refers, in particular, to C1-5 straight-chain alkyls. In other embodiments, “alkyl” refers, in particular, to C1-5 branched-chain alkyls.


The term “mercapto” or “thio” refers to the —SH group.


Provided herein according to some embodiments of the invention are methods of forming co-condensed silica particles via the Stöber process. See, e.g., Stöber, W.; Fink, A.; Bohn, E. J. Colloid Intel face Sci. 1968, 26, 62 (incorporated by reference herein in its entirety). Particle formation under the Stöber process proceeds upon hydrolysis and condensation of silane precursors where the relative hydrolysis rates for the precursors dictate both the speed of particle growth and the likelihood of each silane's incorporation into the silica network. Excessive disparities between reaction rates of different silanes may lead to absence of particle formation upon attempted co-condensation.


Provided according to some embodiments of the invention are methods of forming S-nitrosothiol-functionalized co-condensed silica particles that include reacting a thiol-containing silane and a backbone alkoxysilane in a sol precursor solution that includes water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles include a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix. In some embodiments of the invention, the methods further include reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized co-condensed silica particles.


Any suitable thiol-containing silane may be used. In some embodiments, the thiol-containing silane includes a primary thiol, in some embodiments, a secondary thiol, and in some embodiments, a tertiary thiol. Combinations of different silanes may also be used. A suitable thiol-containing silane will be a silane that will allow for particle formation, and in some embodiments, monodisperse particle formation. Thus, some thiol-containing silanes may be suitable with some backbone alkoxysilanes and not suitable with others. In some embodiments, the primary thiol-containing silane is mercaptopropyltrimethoxysilane. In some embodiments, the tertiary thiol alkoxysilane has the following structure: (OR)(OR′)(OR″)Si(Rx), wherein R, R′ and R″ are each independently H, alkyl or substituted alkyl and Rx is functional group that comprises a tertiary thiol group. In particular embodiments, the tertiary thiol alkoxysilane has the structure:




embedded image



wherein R, R′ and R″ are each independently H, alkyl or substituted alkyl and n is 0-10. In some embodiments, R, R′ and R″ are each independently alkyl and n is 0-5. Furthermore, in particular embodiments of the invention, the tertiary thiol is a compound having the structure:




embedded image


Any suitable backbone alkoxysilane may be used. As used herein, the term “backbone alkoxysilane” refers to an alkoxysilane that does not contain a thiol functional group. Examples include tetramethoxysilane, tetraethoxysilane, methyltrimethoxysilane, methyltriethoxysilane and butyltrimethoxysilane. A suitable backbone silane will be a silane that will allow for particle formation, and in some embodiments, monodisperse particle formation.


Any suitable concentration of water may be used. In some embodiments, the water concentration in the sol precursor solution is in a range of about 8 M to about 32.5 M.


In some embodiments, a catalyst, such as an ammonia catalyst, is included in the sol precursor solution. Any suitable concentration of catalyst may be used. However, in some embodiments, an ammonia catalyst is included in the sol precursor solution, in some embodiments, at a concentration in a range of about 1.9 M to about 5.5 M.


In particular embodiments of the invention, mercaptopropyltrimethoxysilane and tetramethoxysilane are reacted in the presence of water and an ammonia catalyst to form thiol-functionalized co-condensed silica particles. In some embodiments, the reaction occurs in a solution that includes mercaptopropyltrimethoxysilane and tetramethoxysilane at a total silane monomer concentration in a range of about 0.1 M to about 0.4 M, wherein the silane monomer includes about 25 to about 85 mol % mercaptopropyltrimethoxysilane. In some embodiments, water is present in the solution at a concentration in a range of about 8.0 to about 32.5 M and the ammonia catalyst is present at a concentration in a range of about 1.9 M to about 5.5 M.


In some embodiments of the invention, mercaptopropyltrimethoxysilane and tetraethoxysilane are reacted in the presence of water and an ammonia catalyst to form thiol-functionalized co-condensed silica particles. In some embodiments, the reaction occurs in a solution that includes mercaptopropyltrimethoxysilane and tetraethoxysilane at a total silane monomer concentration in a range of about 0.1 M to about 0.4 M, wherein the silane monomer includes about 75 to about 85 mol % mercaptopropyltrimethoxysilane. In some embodiments, water is present in the solution at a concentration in a range of about 8.0 to about 32.5 M and the ammonia catalyst is present at a concentration in a range of about 1.9 M to about 5.5M.


In some embodiments, methods of forming thiol-functionalized co-condensed silica particles include reacting a tertiary thiol-containing silane and a backbone alkoxysilane in the presences of water and an ammonia catalyst to form thiol-functionalized co-condensed silica particles. In some embodiments, the reaction occurs in a solution that includes tertiary thiol-containing silane and alkoxysilane at a total silane monomer concentration in a range of about 0.1 M to about 0.4 M, wherein the silane monomer includes about 25 to about 85 mol % tertiary thiol-containing silane. In some embodiments, water is present in the solution at a concentration in a range of about 8.0 to about 32.5 M and the ammonia catalyst is present at a concentration in a range of about 1.9 to about 5.5 M.


The sol precursor solution may also be stirred/agitated as known to those of skill in the art, and other additives or silane monomers used in sol chemistry may be included in some embodiments of the invention.


In some embodiments of the invention, methods provided herein may be used to form nitrosothiol-functionalized co-condensed silica particles, which in some embodiments, are monodisperse. As used herein, the term “monodisperse” refers to particles having a uniform particle size, in some embodiments, having an average particle diameter ±100 nm as measured from electron micrographs; a Z-average ±60 nm as measured from dynamic light scattering; and/or having a polydispersity index ≦0.1 as measured via dynamic light scattering. In some embodiments, the methods described herein provide monodisperse particles having an average particle diameter of less than 100 microns, and in some embodiments, less than 1 micron. In particular embodiments, the methods used herein may provide monodisperse particles having an average particle diameter in a range of about 10 nm to about 100 μm. In some embodiments, the particles have an average particle diameter in a range of about 200 to about 700 nm.


Any suitable method of nitrosating the thiol-functionalized co-condensed silica particles may be used. Further, any suitable nitrosating agent may be used. However, in some embodiments, the nitrosating agent includes acidified sodium nitrite, alkyl nitrites, including tertbutyl nitrite and isopentyl nitrite, and various nitrogen oxides including nitrous oxide, N2O3, N2O4 and NO2. Examples of nitrosation may be found in Williams, D. L. H. Acc. Chem. Res. 1999, 32, 869, the contents of which are incorporated herein by reference in their entirety.


In some embodiments of the invention, the nitrosation chemistry conserves particle size integrity and yields monodisperse S-nitrosothiol-functionalized co-condensed silica particles. No changes in particle size have been observed following addition of the nitric oxide functionality to the macromolecular structure, a drawback that has been observed with other nitrosothiol-modified macromolecular donors. Furthermore, as shown below in the Examples, the thiol-functionalized co-condensed silica particles may be sonicated prior to nitrosation without deleteriously affecting the NO storage and/or morphology of the particles.


The co-condensed silica particles may include S-nitrosothiol groups throughout the particle, and as such, may provide enhanced NO storage properties. For example, in some embodiments of the invention, provided are S-nitrosothiol-functionalized co-condensed silicas particles that have an NO storage in a range of about 0.01 μmol to about 10 μmol NO per mg particle, and in some embodiments, 0.09 μmol to about 4.40 μmol NO per mg particle.


The incorporation of the S-nitrosothiol groups throughout the interior of the silica particle structure may also afford unexpected stability. Glutathione and other thiols are known to one skilled in the art to be a vial trigger for RSNO decomposition and release a variety of NOx species. In some embodiments of the invention, the low porosity of the S-nitrosothiol-functionalized co-condensed silica particles protect the RSNO donors from premature decomposition by glutathione or other blood components, adding a level of nitric oxide stability when used in drug delivery applications.


EXAMPLES
Preparation of NAPTMS
Synthesis of N-Acetyl Penicillamine (NAP) Thiolactone

Acetic anhydride (96 mmol, 9.80 g) was added dropwise to a well stirred solution of D-(−) penicillamine (40 mmol, 5.97 g) in pyridine (50 mL) at 0° C. After 30 min, the flask was removed from ice and allowed to stir at room temperature for 15 h. The resultant orange solution was partitioned between chloroform and dilute HCl and washed 4× with dilute HCl. After drying over MgSO4, the organic phase was evaporated to yield an orange residue. The residue was first dissolved in absolute ethanol (20 mL), and then precipitated in pentane at −78° C. The light yellow crystalline product was isolated by filtration (2.07 g, 30%). 1H NMR (CDCl3) δ1.65 (s, CH3), 1.86 (s, CH3), 2.05 (s, NHCOCH3), 5.68-5.70 (d, CH(CH3)2), 6.56 (NHCOCH3). 13C NMR (CDCl3) δ 22.52 (NHCOCH3), 26.20 (CH(CH3)2), 30.22 (CH(CH3)2), 51.23 (CH), 169.37 (NHCOCH3), 192.21 (SCO).


Synthesis of N-Acetyl Penicillamine Propyltrimethoxysilane (NAPTMS). APTMS (10 mmol, 1.78 g). was added to a stirring solution of NAP thiolactone (10 mmol, 1.72 g) in methylene chloride (20 mL). The light yellow solution was stirred for 4 h at room temperature before distillation of the methylene chloride to yield NAPTMS as a viscous clear oil. 1H NMR (CDCl3) δ 0.54 (t, SiCH2), 1.24 and 1.39 (s, CH(CH3)2SH), 1.54 (m, SiCH2CH2), 1.96 (s, NHCOCH3), 2.96 and 3.21 (m, SiCH2CH2CH2), 3.44 (s, Si(OCH3)3), 4.63 (d, CHC(CH3)2SH), 6.99 (d, CHNHCOCH3), 7.70 (t, CH2NHCOCH). 13C NMR (CDCl3) δ □6.59 (SiCH2), 22.42 and 22.97 (CH(CH3)2SH), 28.64 (NHCOCH3), 30.80 (SiCH2CH2), 41.93 (CHC(CH3)2SH), 46.23 (SiCH2CH2CH2), 50.35 (Si(OCH3)3), 60.32 (CHC(CH3)2SH), 169.64 (CHNHCOCH3), 170.17 (CHCONH).


The preparation of tertiary thiol-based precursors was investigated for the development of biomedical devices/therapeutics with continuous and photoactivatable NO release. A NAP thiolactone was thus synthesized to design such a precursor for the synthesis of NO-releasing xerogels. Penicillamine was reacted in the presence of acetic anhydride to generate the NAP thiolactone in situ. After characterization by 1H and 13CNMR, the NAP thiolactone was directly coupled with APTMS to result in a tertiary thiol-bearing silane, referred to as NAPTMS (see FIG. 1). Successful synthesis of this tertiary thiol-bearing silane was verified via 1HNMR characterization (FIG. 2).


Example 1
MPTMS

Ratios of mercaptosilane and alkoxysilane (25-85 mol % MPTMS, balance TMOS or TEOS) were added either as a bolus injection or dropwise via a Kent Scientific Genie Plus syringe pump at a flow rate of 0.25-3.0 mL/min through an 18.5 gauge needle to a solution of ethanol, water, and ammonium hydroxide. Solution was stirred for 2 h at room temperature, collected via centrifugation at 4500 rpm (10 mins), washed twice with 40 mL EtOH, recollected, and dried overnight at ambient conditions.


Our initial attempt to synthesize thiol-containing silica particles was based on a bolus injection of 3-mercaptopropyltrimethoxysilane (MPTMS) and alkoxysilane into EtOH/NH4OH solution, The resulting concentrations of ammonia, water and total silane were 3.3, 8.0, and 0.2 M, respectively. Tetramethoxysilane (TMOS) proved to be a sufficient backbone silane for co-condensation with MPTMS as their combination (at various mole percentages) resulted in the formation of a white precipitate. (˜300 mg yield).


As indicated by solution turbidity, a marked increase in reaction time was observed upon increasing the concentration of MPTMS up to 85 mol %. At this concentration, the time to form a visible product after combining the silanes was roughly 15 min. Product formation at MPTMS concentrations >85 mol % was not observed. The inability to form particles at greater MPTMS concentrations may be attributed to the disparate hydrolysis rates between the silanes, suggesting that co-condensation requires a minimum concentration of the more readily hydrolyzable silane (i.e., TMOS) to initiate particle growth.


Materials synthesized via the co-condensation of MPTMS and tetraethoxysilane (TEOS) formed only in the concentration range of 75-85 mol % MPTMS. In contrast to the TMOS system, products with lower concentrations of MPTMS (e.g., 25 mol %) did not form using TEOS as a backbone, even at prolonged reaction times (up to 48 h).


Example 2
MPMDMS

Another thiol-functionalized monomer, 3-mercaptopropylmethyldimethoxysilane (MPMDMS), was also investigated. Unfortunately, the product yield (˜5 mg) formed using MPMDMS with either TMOS or TEOS was significantly lower than MPTMS. The substitution of one of the hydrolyzable methoxy groups with a nonhydrolyzable methyl linkage in MPMDMS (vs. MPTMS) appears to decrease the resulting hydrolysis rate under basic conditions, possibly due to the inductive effect of electron density donation to the Si atom. As a result, the reaction with hydroxide anion to hydrolyze the silane may be inhibited. Particle formation may even be further limited as each MPMDMS molecule is capable of forming only two siloxane bridges. Consequently, particle formation using MPMDMS was unsuccessful.


Example 3
Characterization of First Generation Mercaptosilane-Based Silica Particles

Solid-state cross polarization/magic angle spinning (CP/MAS) 29Si (71.548 MHz frequency) nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker 360 MHz DMX spectrometer (Billerica, Mass.). Particles were packed into 4 mm rotors and spun at 8.0 kHz. Spectra were collected at 5000 scans with the determination of chemical shifts in parts per million relative to an external TMS standard. Nitric oxide release was measured in real time (1 sec intervals) using 5 a Sievers NOATM 280i Chemiluminescence Nitric Oxide Analyzer (NOA) (Boulder, Colo.). Calibration of the NOA was performed with both air passed through a Sievers NO zero filter and 26.39 ppm NO gas (balance N2). Nitric oxide-releasing particles were immersed in 25 mL of deoxygenated solution and sparged with an 80 mL min−1 N2 stream. Additional N2 was supplied to the reaction flask to match the collection rate of the NOA at 200 mL min−1.


Temperature control was maintained using a water bath at 37° C. Thermal and photo-initiated NO release were studied by conducting the experiments in 500 μM DTPA (pH 7.4 PBS) to chelate trace copper and illuminating the sample flask with 60, 100, and 200 W incandescent bulbs, respectively. Copper-initiated NO release was studied by adding the particles to 25 mL of 10 or 25 μM CuBr2(aq). The NOA sample flask was shielded from light with aluminum foil for experiments where light was not the intended initiator of NO release. Particle size was determined using a Zetasizer Nano ZS Particle Size and Zeta Potential Dynamic Light Scattering (DLS) Instrument (Malvern, UK). Samples were suspended in PBS at a concentration of 1 mg mL-1 and sonicated for 15 min prior to analysis. Scanning electron micrographs were recorded on a Hitachi S-4700 Scanning Electron Microscope (Pleasanton, Calif.).


To confirm the incorporation of mercaptosilane within the silica network and compare various compositions, solid-state 29Si cross polarization/magic angle spinning nuclear magnetic resonance (CP/MAS NMR) was used to characterize the MPTMS/TMOS products as a function of MPTMS concentration: Silicon atoms of tetraalkoxysilanes appear in the NMR spectra as Qn bands while those of organotrialkoxysilanes appear as Tn bands. In both cases, n denotes the number of siloxane bonds attached to the Si atom. The greater number of siloxane bonds to the Si atom, the further the NMR band shifts upfield. FIG. 3 shows silica synthesized with (A) 0, (B) 25, (C) 40, (D) 60, (E) 75, and (F) 85 mol % MPTMS (balance TMOS). Particles synthesized entirely from TMOS exhibited only Q bands. With increasing MPTMS concentration in the solution used to prepare the particles, the T bands increased relative to the Q bands, confirming greater incorporation of MPTMS in the silica particle.


Sulfur weight percent of each composition was determined using elemental analysis and further corroborated the covalent incorporation of the mercaptosilane. The weight percent of sulfur in the silica was 4.92, 7.11, 11.67, 13.56 and 17.30 for the 25, 40, 60, 75 and 85 mol % MPTMS (balance TMOS) compositions, respectively. The TEOS-based particles were found to have sulfur weight percents of 16.15 and 19.34 for 75 and 85 mol % MPTMS, respectively. As expected, the weight percent of sulfur increased linearly with increasing MPTMS concentration in the initial solution.


Dynamic light scattering (DLS) measurements indicated that the sample was too polydisperse to accurately measure the particle size. Scanning electron micrographs (SEMs) further indicated that the thiol-containing silica was polydisperse and exhibited nonspherical morphology more indicative of colloidal silica than individual particles. (data not shown).


Example 4
Variation of Water, Ammonia and Silane Concentrations and Feed Rate

We systematically varied synthetic parameters (i.e., water, ammonia, and silane concentrations) to tune the resulting particle morphology and achieve a more spherical shape. The composition of 25 mol % MPTMS (balance TMOS) was chosen as the model system for comparison due to minimal organic character.


For MPTMS particles, we found that increasing the water content from 8.0 to 16.2 M promoted the formation of spherical particles and prevented aggregation/fusion. Lower ammonia concentrations were shown to result in particles that lacked spherical shape and aggregated. Thus, we discovered that the ratio of water and ammonia to silane was a critical factor during particle synthesis. Upon considering all the data, we determined that the most spherical and monodisperse particles were the 25 mol % MPTMS (balance TMOS) particles were formed using 5.5 M ammonia, 0.1 M total silane, and 16.2 M water. Of note, the product yield (˜70 mg) with this synthesis was lower than that obtained for the polydisperse colloidal silica. The decreased yield was due to the 4-fold decrease in the silane concentration used in the optimized synthesis.


Next, the concentration of MPTMS in the solution was increased to enhance the degree of thiol functionality and potential NO storage of the particles. FIG. 4 depicts the resulting particles as the concentration of MPTMS was increased from 25-85 mol % and backbone alkoxysilane varied between TMOS and TEOS. The particles were synthesized with 16.0 M water, 5.5 M ammonia, and 0.1 M silane.


As with the polydisperse colloidal silica system, the formation of particles was not observed for 25-60 mol % MPTMS (balance TEOS). Only 75 and 85 mol % MPTMS concentrations yielded particles with TEOS, illustrating how disparities in hydrolysis and condensation kinetics adversely affect and hinder particle formation. The 75 mol % MPTMS (balance TEOS) particles formed in a narrow size distribution and exhibited spherical morphologies (FIG. 4F). In contrast, 85 mol % MPTMS (balance TEOS) particles appeared aggregated (FIG. 4G). When using TMOS, 25 mol % MPTMS was the only concentration that yielded spherical, monodisperse particles (FIG. 4A). Particles with ≧40 mol % MPTMS (balance TMOS) exhibited ideal morphologies, but with concomitant bimodal size distributions (FIG. 4B-E).


To remedy the bimodal size distribution that was observed for certain MPTMS compositions, we evaluated the effect of a silane feed rate of 0.5 mL min−1 on particle morphologies throughout the range of compositions (FIG. 5). The slower feed rate improved the dispersity of the already narrow size distribution for 25 mol % MPTMS (FIG. 5A). A pronounced improvement in the monodispersity was also noted for 40 mol % MPTMS (balance TMOS, FIG. 5B), with SEM indicating a particle diameter of 293±24 nm. Slower silane feed rates (e.g., 0.25 mL min−1) resulted in slight monodispersity improvements (data not shown), but at lower yields (e.g., ˜40 vs. 70 mg for 40 mol % MPTMS (balance TMOS) composition). Thus, 0.5 mL min−1 was determined to be the optimal feed rate as it allowed for a balance between sufficient particle yield and monodispersity. Similar to 25 mol % MPTMS (balance TMOS), the monodispersity of 75 mol % MPTMS (balance TEOS) improved, while the 85 mol % MPTMS (balance TEOS) system remained aggregated (FIGS. 5F and 5G, respectively).


Additionally, the product yield increased to ˜170 mg for these two compositions and can be attributed to the greater concentration of the larger MPTMS in the particles. Unfortunately, the semi-batch process proved problematic for 60, 75, and 85 mol % MPTMS (balance TMOS) particles. As shown in FIG. 5C-E, the slowed silane addition resulted in both aggregation and the formation of a large silica network rather than monodisperse, spherical particles. To examine this phenomenon further, silane feed rates were varied (0.25-3.0 mL min−1) for 60 mol % MPTMS (balance TMOS). Feed rates <2.0 mL min−1 resulted in polydisperse, aggregated silica, while faster feed rates (2.0-3.0 mL min−1) produced particles of a bimodal size (data not shown).


We then attempted to decrease the size of the particles to improve particle monodispersity. The 75 mol % MPTMS (balance TEOS) particles were chosen as a model system to examine the effect of the water concentration on particle size and morphology. As shown in FIG. 6, 75 mol % MPTMS (balance TEOS) was synthesized with (A) 47.0, (B) 42.0, (C) 40.6, (D) 36.5, (E) 32.5, and (F) 24.9 M water. Water concentrations ≧40.6 M favored rapid silane hydrolysis and condensation kinetics, leading to a highly condensed network rather than discrete, spherical particles. At a water concentration of 36.5 M, discrete particles were formed, but with morphologies featuring excessive aggregation. Monodisperse particles (333±48 nm) were first observed at a slightly lower water concentration (32.5 M). Particle size increased with decreasing water concentrations (456±68 nm and 635±63 nm for 24.9 and 16.2 M, respectively). Furthermore, the smaller particle sizes were accompanied with slightly lower yields for each composition. The yields for 75 mol % MPTMS (balance TEOS) particles were ˜65, 150, and 170 mg for water concentrations of 32.5, 24.9, and 16.2 M, respectively. The differences in yield may be factors of the efficiency of particle collection (i.e., centrifugation rpm and duration) for the smaller particles rather than chemical differences.


The appropriate water concentrations (32.5 and 24.9 M) were next used to tune particle size and reduce the bimodal distribution characteristic of the 60, 75, and 85 mol % MPTMS (balance TMOS) particles. As shown in FIG. 7, the intermediate water concentration (24.9 M) yielded particles with sizes of 179±22 and 196±25 nm for the 25 and 40 mol % MPTMS (balance TMOS) compositions, respectively. The greater water concentration (32.5 M) drastically increased the reaction kinetics for the mostly TMOS-based systems, resulting in highly-fused silica networks. Increasing the concentration of MPTMS (75 mol %) yielded monodisperse, spherical particles of 363±51 and 279±49 nm using 24.9 and 32.5 M water, respectively. Aggregated and fused particles were formed for the greatest MPTMS concentration (85 mol %) when using 24.9 M water. However, monodisperse particles (440±84 nm) were formed when synthesized with 32.5 M water.


The TEOS-based counterpart to this system behaved similarly by yielding only discrete particles (506±77 nm) when synthesized with the higher water concentration. At lower water amounts, the formation of aggregated particles was noted. The trend of decreasing particle yield with increasing water content that was observed for the 75 mol % MPTMS (balance TEOS) composition was mirrored for all other compositions evaluated. The yields for the 75 mol % (balance TMOS) particles decreased from ˜120 to 60 mg upon increasing the water content from 24.9 to 32.5 M. Likewise, the 25 mol % MPTMS (balance TMOS) particle yield decreased from ˜90 to 20 mg while the 40 mol % MPTMS system exhibited a decrease from ˜50 to 9 mg upon increasing the water concentration from 16.2 to 24.9 M. The yields for both 85 mol % MPTMS compositions (i.e, TMOS and TEOS balance) at a water concentration of 32.5 M were ˜160 mg. Perhaps of greatest significance, the elevated water concentrations used to synthesize the thiol-modified particles successfully resolved the bimodal nature of certain compositions not resolvable using a semi-batch process alone. Of note, 60 mol % MPTMS (balance TMOS) was the only composition that consistently yielded particles of a bimodal nature. Increasing the water content regardless of addition method (bolus vs. semi-batch) resulted in a highly-fused silica network.


Particle sizes were also measured by DLS to corroborate particle monodispersity and size measured using SEM. As shown in Table 1, the DLS measurements were in agreement with the sizes calculated from the SEM images. The slightly increased average diameters observed with DLS may be attributed to particle hydration (DLS measurements conducted in solution). Like SEM, the DLS measurements indicated a narrow size distribution, as evidenced by low polydispersity indices for each composition.













TABLE 1






Water
Particle
Z-Average
Polydis-


Particle composition
content
sizea
sizeb
persity


(mol % MPTMS)
(M)
(nm)
(nm)
index







75% (balance TEOS)
32.5
333 ± 48
416.2 ± 23.4
0.027


75% (balance TEOS)
24.9
456 ± 68
529.6 ± 23.7
0.018


75% (balance TEOS)
16.2
635 ± 63
718.0 ± 51.7
0.046


85% (balance TEOS)
32.5
506 ± 77
668.7 ± 46.0
0.040


25% (balance TMOS)
24.9
179 ± 22
 258.4 ± 15.1c
0.031


25% (balance TMOS)
16.2
252 ± 20
 469.0 ± 24.8c
0.025


40% (balance TMOS)
24.9
196 ± 25
 240.7 ± 17.9c
0.064


40% (balance TMOS)
16.2
293 ± 24
404.8 ± 28.2
0.045


75% (balance TMOS)
32.5
279 ± 49
431.2 ± 29.5
0.043


75% (balance TMOS)
24.9
363 ± 51
507.6 ± 30.8
0.032


85% (balance TMOS)
32.5
440 ± 84
696.2 ± 44.4
0.042






aSize calculated from scanning electron micrographs of n = 120 particles




bSizes acquired from dynamic light scattering measurements in pH 7.4 PBS for n = 3 syntheses




cEthanol used as dispersant








Of note, PBS was used as a dispersant for compositions with a large concentration of MPTMS. However, smaller particles with a large degree of inorganic character (i.e., ≦40 mol % MPTMS) rapidly aggregated in this dispersant and caused erratic DLS measurements. This aggregation may be attributed to a large surface density of protonated silanol groups leading to unfavorable particle interaction. While basic conditions resulted in inconsistent DLS measurements due to particle dissolution, ethanol was a viable alternative dispersant as evidenced by the correlation between DLS and SEM measurements.


Elemental analysis was used to characterize the composition of the particles. As expected, the weight percentages of sulfur in the particles increased accordingly with the MPTMS mol % used to make the particles indicating incorporation of the thiol functionality (Table 2).













TABLE 2







Particle composition
Water content
Sulfur contenta



(mol % MPTMS)
(M)
(wt %)









75% (balance TEOS)
32.5
13.83 ± 3.01



75% (balance TEOS)
24.9
16.01 ± 1.71



75% (balance TEOS)
16.2
15.62 ± 1.90



85% (balance TEOS)
32.5
20.02 ± 3.88



25% (balance TMOS)
24.9
<0.0b



25% (balance TMOS)
16.2
 0.51 ± 0.36



40% (balance TMOS)
24.9
 1.09 ± 0.58



40% (balance TMOS)
16.2
 3.08 ± 2.57



75% (balance TMOS)
32.5
18.29 ± 5.34



75% (balance TMOS)
24.9
15.30 ± 5.32



85% (balance TMOS)
32.5
20.55 ± 5.70








aAverage weight percents are calculated from n = 3 syntheses





bWeight percent was less than instrument limit of detection







Syntheses promoting the formation of discrete, spherical particles tended to be preferentially derived from one precursor as evidenced by a large gap in the transition from 40 to 75 mol % MPTMS (wt % 3.08±2.57 and 15.62±1.90, respectively). These values were in marked contrast to the sulfur wt % of the colloidal silica. Although the increased sulfur wt % were more linearly proportional for the colloidal silica, the lack of discrete, spherical particles was not ideal. The comparison of the two systems (colloidal vs. discrete particles) and syntheses reveals that a balance exists between silane incorporation and certain design criteria.


Example 5
Synthesis of Particles with NAPTMS

Procedure for 25% NAPTMS Balance TMOS/TEOS:






    • 1. Dissolved 85.4 mg NAPTMS (tertiary precursor) in 3.95 mL of ethanol by vortexing

    • 2. To the reaction mixture added 4.09 mL of water then added TMOS/ethanol mixture (71.9 μL TMOS and 200 μL ethanol) via syringe pump at a rate of 1.0 mL/min.

    • 3. Added 6 mL of 5M HCL and let sonicate (120%) for 1 hour.

    • 4. Added 4 mL of ammonium hydroxide and allowed to sonicate (120%) for 30 minutes.


      Final Concentrations TMOS and TEOS Particles:




















[Silane] = 0.0352M



[Water] = 42.8M



[HCl] = 1.57M



[Ethanol] = 3.85M



[NH3] = 3.43M











Size Characterization:















Particle
Particle size
Z-average size



Composition
(nm) SEM
(nm) DLS
PDI







25% NAPTMS
802.8 ± 116
607.3 ± 28.9
0.17 ± 0.072


balance TMOS


25% NAPTMS
820.2 ± 95 
760.6 ± 27.3
0.16 ± 0.038


balance TEOS









Example 6
Nitrosation of Mercaptosilane-Based Silica Particles

Thiols within the particles were nitrosated via reaction with nitrous acid. 12 Particles (˜200 mg) were first added to 4 mL methanol (MeOH). While stirring, 2 mL of hydrochloric acid (5 M) was added to the suspension. A 2 mL aqueous solution containing sodium nitrite (2× molar excess to thiol) and DTPA (500 μM) was then added to the particle suspension, and the mixture stirred for 2 h in the dark and on ice. Particles were collected by centrifugation at 4500 rpm (5 min), washed with 40 mL chilled 500 μM DTPA(aq), recollected, washed with 40 mL chilled MeOH, recollected, and vacuum dried for 30 min while shielded from light. Particles were stored at −20° C. in vacuo until further study.


The MPTMS-modified particles were nitrosated to enable NO storage and release. Briefly, the particles were treated with acidified sodium nitrite, generating nitrous acid, a nitrosating agent that reacts with thiols to form RSNOs (see Eq 1).

RSH+HNO2custom characterRSNO+H2O  (1)


Since S-nitrosothiols prepared from primary thiols absorb light at 330-350 and 550-600 nm, successful RSNO formation was confirmed by the resulting red color of the particles after nitrosation. Furthermore, the intensity of the color increased with MPTMS mol % indicating greater RSNO formation.


As widely known, S-nitrosothiols decompose via a multitude of pathways (FIG. 8). Both photo and thermal irradiation of RSNOs result in homolytic cleavage of the S—N bond, yielding NO and a thiyl radical. The thiyl radical may subsequently react with an RSNO to generate a disulfide and an additional equivalent of NO. Cu(I), resulting from the reduction of Cu(II) via trace thiolate ions, has been shown to be active in a catalytic RSNO decomposition mechanism. Transnitrosation between a thiol and an RSNO may also occur, resulting in the transfer of the nitroso functionality and formation of a new RSNO species that may decompose via the aforementioned pathways.


To assess the NO storage and release, RSNO-modified particles (˜2 mg) were added to 500 μM DTPA (pH 7.4 PBS) at a temperature of 0° C., while measuring the ensuing NO release as a function of photolytic decomposition. As shown in FIG. 9A, RSNO-modified silica particles exhibited photo-initiated NO release upon exposure to broadband, white light. Greater irradiation levels (i.e., power) resulted in elevated NO release from the particles. Of note, low levels of NO release (˜15 ppb mg−1 s−1) were observed at 0° C. and in the dark (FIG. 9A inset). Others have shown that oxygen may react with NO to form dinitrogen trioxide (N2O3), an oxidant that also decomposes RSNOs. Elimination of oxygen from the storage environment of the RSNO-modified particles would thus be expected to increase the NO storage stability of the particles. Indeed, no significant loss in NO release capacity was measured upon storing the particles for 2 months at −20° C. in vacuo and in the dark.


Due to the rapid kinetics of the photo-initiated decomposition, total NO storage of the particles was assessed by exposing the particles to 200 W of broadband light. Indeed, >95% of the NO stored was released after 5 h of irradiation at 200 W. As given in Table 3, the total NO released from the particles ranged from 0.09-4.39 μmol mg−1. These levels of NO storage are an order of magnitude larger than previously reported RSNO-modified silica particles. Using the average sulfur weight percents in conjunction with the average NO storage values, the percent conversion of thiol to RSNO for the different particle compositions was calculated to be 58-78% for the 75 and 85 mol % MPTMS/TMOS and MPTMS/TEOS systems. The 25 and 40 mol % MPTMS particles were found to have lower thiol to RSNO conversions (54-63%).













TABLE 3







Particle composition
Water content
Total NO releaseda



(mol % MPTMS)
(M)
(μmol mg−1)









75% (balance TEOS)
32.5
3.24 ± 0.61



75% (balance TEOS)
24.9
3.58 ± 0.39



75% (balance TEOS)
16.2
3.15 ± 0.60



85% (balance TEOS)
32.5
3.95 ± 0.66



25% (balance TMOS)
24.9
0.09 ± 0.02



25% (balance TMOS)
16.2
0.10 ± 0.02



40% (balance TMOS)
24.9
0.34 ± 0.02



40% (balance TMOS)
16.2
0.52 ± 0.22



75% (balance TMOS)
32.5
3.31 ± 0.85



75% (balance TMOS)
24.9
3.73 ± 0.62



85% (balance TMOS)
32.5
4.39 ± 0.02








aAverages are calculated from n = 3 syntheses and after 5 h of 200 W irradiation







The effect of copper on NO release was investigated as a function of copper concentration. These assays were performed using Cu(II) via CuBr2 due to the insolubility of Cu(I) compounds in aqueous solutions. As expected, the NO release from the RSNO-modified particles correlated with the copper concentration (FIG. 9B) with the greatest copper concentration examined (25 μM) generating the maximum NO release (˜45 ppb mg−1 s−1).


The use of RSNO-modified particles for biomedical application likely necessitates an NO release trigger other than light or large concentrations of free copper ions. We thus evaluated NO release from the particles via thermal degradation at 37° C. using 75 mol % MPTMS (balance TEOS, 718.0±51.7 nm) as a model system. Particles were introduced into 500 μM DTPA (pH 7.4 PBS), maintained at 37° C. and shielded from external light while monitoring NO release over 48 h (Table 4). Under these conditions, the particles released a total of 1.17 μmol NO mg−1 with a corresponding half life of 2.95 h. When compared to the total amount released after 5 h using 200 W irradiation (3.15 μmol mg−1, Table 3), the discrepancy may be attributed to inability to measure NO at low levels beyond 48 h and/or loss of NO through its reaction with oxygen present in the soak solutions. As evident by a pink hue, the particles still contained a portion of their NO payload even after 48 h of release.












TABLE 4







Time
Instantaneous NO release



(h)
(ppb mg−1 s−1)a



















0
1205.7 ± 22.4



0.5
481.2 ± 7.7



1
355.7 ± 7.7



6
 74.9 ± 0.7



12
 33.2 ± 0.4



24
 12.6 ± 0.2



48
 2.50 ± 0.07








aAverages are calculated from n = 3 syntheses







Example 7
Thermal Initiated NO Release Characterization of Primary and Tertiary RSNO Particles

For each particle composition, approximately 3 mg of particles were added to the collection flask containing PBS (500 μM DTPA) and the NO release monitored over 75 min. The NO storage and release characteristics are shown in Table 5.












TABLE 5






t[NO]total
[NO]mmax



Particle
(μmol mg−1)
NO release
time to get to


Composition
at 75 minutes
(pmol mg−1)
max (min)


















75% MPTMS
0.878
262
1.6


balance TEOS


(primary RSNO)


25% NAPTMS
1.70 × 10−3
0.913
32


balance TMOS


(tertiary RSNO)


25% NAPTMS
4.13 × 10−4
1.31
75


balance TEOS


(tertiary RSNO)









The NO storage and release characteristics of the 25% NAPTMS sample while under irradiation were also investigated. Using 200 W illumination, and 0.3 m distance, the results are shown in Table 6.












TABLE 6






t[NO]total
[NO]mmax



Particle
(μmol mg−1)
NO release
t to get to


Composition
at 75 minutes
(pmol mg−1)
max (min)







25% NAPTMS
0.205
61.5
10.5


balance TMOS


(tertiary RSNO)









The results shown in Tables 5 and 6 shown that NO stability of the particles can be significantly increased by using a tertiary nitrosothiol-functionalized silica particles.


Example 8
Influence of Particle Sonication Before/after Nitrosation

Experiment 8A: Nitrosated Particles No Sonication






    • 1. Nitrosate 15 mg of particles in methanol, 5M HCl, and 2 mol X (vs. thiol) of NaNO2/500 uM DTPA.

    • 2. Collect and wash with cold dtpa and cold methanol. Dry under vacuum for 45 min in dark (covered with foil).

    • 3. Add 1 mg of nitrosated particles to 5 mL PBS (DTPA)

    • 4. Expose to 200 W illumination (30 cm from inside bottom of box)


      Experiment 8B: Particle Nitrosation then Sonication

    • 1. Nitrosate 15 mg of particles in methanol, 5M HCl, and 2 mol X (vs. thiol) of NaNO2/500 uM DTPA.

    • 2. Collect and wash with cold dtpa and cold methanol. Dry under vacuum for 45 min in dark (covered with foil).

    • 3. Add 1 mg of nitrosated particles to 5 mL of PBS (DTPA) and sonicate for 30 min on ice at amplitude=50%.

    • 4. Expose to 200 W illumination (30 cm from inside bottom of box)


      Experiment 8C: Particle Sonication (30 Min at Amplitude=50%) then Nitrosation

    • 1. Sonicate 15 mg of non-nitrosated particles in 4 mL of Methanol on ice for 30 minutes on ice at amplitude=50%.

    • 2. Nitrosatesonicated particles in 4 mL of methanol, 5M HCl, and 2 mol X (vs. thiol) of NaNO2/500 uM DTPA.

    • 3. Collect and wash with cold dtpa and cold methanol. Dry under vacuum for 45 min in dark (covered with foil).

    • 4. Add 1 mg of nitrosated particles to 5 mL PBS (DTPA)

    • 5. Expose to 200 W illumination (30 cm from inside bottom of box)


      Experiment 8D: Particle Sonication (60 Min at Amplitude=50%) then Nitrosation

    • 1. Sonicate 15 mg of non-nitrosated particles in 4 mL of Methanol on ice for 60 minutes on ice at amplitude=50%.

    • 2. Nitrosatesonicated particles in 4 mL of methanol, 5M HCl, and 2 mol X (vs. thiol) of NaNO2/500 uM DTPA.

    • 3. Collect and wash with cold dtpa and cold methanol. Dry under vacuum for 45 min in dark (covered with foil).

    • 4. Add 1 mg of nitrosated particles to 5 mL PBS (DTPA)

    • 5. Expose to 200 W illumination (30 cm from inside bottom of box)


      The results of Experiments 8A-8D are shown in



















Total NO




Experiments
Concentration
Duration of NO


(see above)
(μmol mg−1)
Release (h)
No. of Experiments







7A
1.46 ± 0.16
24
N = 3


7B
1.05 ± 0.13
24
N = 3


7C
1.38 ± 0.37
24
N = 3


7D
1.36 ± 0.23
24
N = 3










SEM images of the particles formed in Example 7A are provided in FIG. 10. SEM images of the particles formed in Example 7C are provided in FIG. 11. SEM images of the particles formed in Example 7D are shown in FIG. 12. These results show that particle morphology and nitric oxide storage is not significantly influenced by the sonication procedure. Thus, sonicating particles may be used to narrow size distribution and/or making smaller particles.


In the drawings and specification, there have been disclosed embodiments of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention being set forth in the following claims.

Claims
  • 1. S-nitrosothiol-functionalized co-condensed silica particles having an NO storage in a range of about 0.01 μmol to about 10 μmol NO per mg particle.
  • 2. The S-nitrosothiol-functionalized co-condensed silica particles of claim 1, wherein the particles have an NO storage in a range of about 0.09 μmol to about 4.40 μmol NO per mg particle.
  • 3. The S-nitrosothiol-functionalized co-condensed silica particles of claim 1, wherein the particles comprise a polysiloxane matrix and have at least some nitrosothiol functional groups distributed within the polysiloxane matrix.
  • 4. The S-nitrosothiol-functionalized co-condensed silica particles of claim 1, wherein the S-nitrosothiol functional groups comprise primary nitrosothiol functional groups.
  • 5. The S-nitrosothiol-functionalized co-condensed silica particles of claim 1, wherein the S-nitrosothiol functional groups comprise tertiary nitrosothiol functional groups.
  • 6. S-nitrosothiol-functionalized monodisperse co-condensed silica particles having an average particle diameter in a range of about 200 nm to about 700 nm.
  • 7. The S-nitrosothiol-functionalized co-condensed silica particles of claim 6, wherein the particles comprise a polysiloxane matrix and have at least some nitrosothiol functional groups distributed within the polysiloxane matrix.
  • 8. The S-nitrosothiol-functionalized co-condensed silica particles of claim 6, wherein the S-nitrosothiol functional groups comprise primary nitrosothiol functional groups.
  • 9. The S-nitrosothiol-functionalized co-condensed silica particles of claim 6, wherein the S-nitrosothiol functional groups comprise tertiary nitrosothiol functional groups.
  • 10. The S-nitrosothiol-functionalized co-condensed silica particles of claim 6, wherein the particles are formed from the condensation of a thiol-containing silane and a backbone alkoxysilane.
  • 11. The S-nitrosothiol-functionalized co-condensed silica particles of claim 10, wherein the thiol-containing silane is a tertiary thiol-containing silane.
  • 12. A method of forming the S-nitrosothiol-functionalized monodisperse co-condensed silica particles of claim 6, the method comprising: reacting a thiol-containing silane and a backbone alkoxysilane in a sol precursor solution that comprises water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles comprise a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix; andreacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized monodisperse co-condensed silica particles.
  • 13. The method of claim 12, wherein the thiol-containing silane comprises a primary thiol-containing silane.
  • 14. The method of claim 13, wherein the primary thiol-containing silane is mercaptopropyltrimethoxysilane and the backbone alkoxysilane is tetraethoxysilane.
  • 15. The method of claim 13, wherein the primary thiol-containing silane comprises mercaptopropyltrimethoxysilane and the backbone alkoxysilane comprises tetramethoxysilane.
  • 16. The method of claim 15, wherein the sol precursor solution comprises an ammonia catalyst at a concentration in a range of about 1.9 to about 5.5 M; wherein the total silane monomer concentration in the sol precursor solution is in a range of about 0.1 M to about 0.4 M;wherein the total silane monomer concentration comprises about 25 to about 85 mol % mercaptopropyltrimethoxysilane; andwherein the water is present in the sol precursor solution at a concentration in a range of about 8.0 to about 32.5 M.
  • 17. The method of claim 12, wherein the thiol-containing silane comprises a tertiary thiol-containing silane.
  • 18. The method of claim 17, wherein the tertiary thiol-containing silane comprises a tertiary thiol having the following structure:
  • 19. The method of claim 18, wherein the tertiary thiol-containing silane has the following structure:
  • 20. The method of claim 18, wherein the backbone alkoxysilane comprises tetraethoxysilane.
  • 21. The method of claim 12, wherein the thiol-functionalized co-condensed silica particles are sonicated prior to reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation under 35 U.S.C. §111(a) of PCT Application No. PCT/US2012/026960, filed on Feb. 28, 2012, which claims the benefit, under 35 U.S.C. §119, of U.S. Provisional Application Ser. No. 61/447,368, filed Feb. 28, 2011, and U.S. Provisional Application No. 61/565,694, filed Dec. 1, 2011, the disclosure of each of which is hereby incorporated by reference herein in its entirety.

STATEMENT OF GOVERNMENT SUPPORT

The present invention was funded in part by government support under grant number 5-R01-EB000708 from the National Institutes of Health. The United States Government has certain rights in this invention.

US Referenced Citations (499)
Number Name Date Kind
4507466 Tomalia et al. Mar 1985 A
4558120 Tomalia et al. Dec 1985 A
4568737 Tomalia et al. Feb 1986 A
4587329 Tomalia et al. May 1986 A
4631337 Tomalia et al. Dec 1986 A
4694064 Tomalia et al. Sep 1987 A
4713975 Tomalia et al. Dec 1987 A
4737550 Tomalia Apr 1988 A
4857599 Tomalia et al. Aug 1989 A
4871779 Killat et al. Oct 1989 A
4985023 Blank et al. Jan 1991 A
4990338 Blank et al. Feb 1991 A
5035892 Blank et al. Jul 1991 A
5045322 Blank et al. Sep 1991 A
5061487 Blank et al. Oct 1991 A
5079004 Blank et al. Jan 1992 A
5380758 Stamler et al. Jan 1995 A
5405919 Keefer et al. Apr 1995 A
5418301 Hult et al. May 1995 A
5428070 Cooke et al. Jun 1995 A
5504117 Gorfine Apr 1996 A
5519020 Smith et al. May 1996 A
5525357 Keefer et al. Jun 1996 A
5574068 Stamler et al. Nov 1996 A
5593876 Stamler et al. Jan 1997 A
5599984 Bianchi et al. Feb 1997 A
5629322 Guthikonda et al. May 1997 A
5632981 Saavedra et al. May 1997 A
5650442 Mitchell et al. Jul 1997 A
5650447 Keefer et al. Jul 1997 A
5665077 Rosen et al. Sep 1997 A
5676963 Keefer et al. Oct 1997 A
5691423 Smith et al. Nov 1997 A
5693676 Gorfine Dec 1997 A
5700830 Korthuis et al. Dec 1997 A
5718892 Keefer et al. Feb 1998 A
5726156 Girten et al. Mar 1998 A
5750573 Bianchi et al. May 1998 A
5753684 Bianchi et al. May 1998 A
5760001 Girten et al. Jun 1998 A
5770645 Stamler et al. Jun 1998 A
5786332 Girten et al. Jul 1998 A
5789447 Wink, Jr. et al. Aug 1998 A
5797887 Rosen et al. Aug 1998 A
5810010 Anbar Sep 1998 A
5814666 Green et al. Sep 1998 A
5814667 Mitchell et al. Sep 1998 A
5821261 Durette et al. Oct 1998 A
5837736 Mitchell et al. Nov 1998 A
5840759 Mitchell et al. Nov 1998 A
5849794 Bianchi et al. Dec 1998 A
5852058 Cooke et al. Dec 1998 A
5854289 Bianchi et al. Dec 1998 A
5859062 Bianchi et al. Jan 1999 A
5861168 Cooke et al. Jan 1999 A
5863890 Stamler et al. Jan 1999 A
5891459 Cooke et al. Apr 1999 A
5891472 Russell Apr 1999 A
5910316 Keefer et al. Jun 1999 A
5932538 Garvey et al. Aug 1999 A
5958427 Salzman et al. Sep 1999 A
5961466 Anbar Oct 1999 A
5962520 Smith et al. Oct 1999 A
5994294 Garvey et al. Nov 1999 A
5994444 Trescony et al. Nov 1999 A
5999843 Anbar Dec 1999 A
6008255 Bianchi et al. Dec 1999 A
6022900 Bianchi et al. Feb 2000 A
6035225 Anbar Mar 2000 A
6043358 Caldwell et al. Mar 2000 A
6045827 Russell Apr 2000 A
6070928 Campbell Jun 2000 A
6087479 Stamler et al. Jul 2000 A
6103275 Seitz et al. Aug 2000 A
6110453 Keefer et al. Aug 2000 A
6143037 Goldstein et al. Nov 2000 A
6147068 Smith et al. Nov 2000 A
6151522 Alfano et al. Nov 2000 A
6160021 Lerner et al. Dec 2000 A
6171232 Papandreou et al. Jan 2001 B1
6174539 Stamler et al. Jan 2001 B1
6180082 Woltering et al. Jan 2001 B1
6180676 Bianchi et al. Jan 2001 B1
6190704 Murrell Feb 2001 B1
6200558 Saavedra et al. Mar 2001 B1
6207855 Toone et al. Mar 2001 B1
6218016 Tedeschi et al. Apr 2001 B1
6232336 Hrabie et al. May 2001 B1
6232434 Stamler et al. May 2001 B1
6238683 Burnett et al. May 2001 B1
6248787 Bianchi et al. Jun 2001 B1
6255277 Stamler et al. Jul 2001 B1
6261594 Smith et al. Jul 2001 B1
6270779 Fitzhugh et al. Aug 2001 B1
6287601 Russell Sep 2001 B1
6290981 Keefer et al. Sep 2001 B1
6291424 Stamler et al. Sep 2001 B1
6294517 Garvey et al. Sep 2001 B1
6299980 Shah et al. Oct 2001 B1
6323211 Garvey et al. Nov 2001 B1
6350467 Demopoulos et al. Feb 2002 B1
6352709 Stamler et al. Mar 2002 B1
6358536 Thomas Mar 2002 B1
6359167 Toone et al. Mar 2002 B2
6359182 Stamler et al. Mar 2002 B1
6369071 Haj-Yehia Apr 2002 B1
6372733 Caldwell et al. Apr 2002 B1
6377321 Khan et al. Apr 2002 B1
6379660 Saavedra et al. Apr 2002 B1
6379691 Tedeschi et al. Apr 2002 B1
6391895 Towart et al. May 2002 B1
6403759 Stamler et al. Jun 2002 B2
6410622 Endres Jun 2002 B1
6417162 Garvey et al. Jul 2002 B1
6432077 Stenzler Aug 2002 B1
6433182 Garvey et al. Aug 2002 B1
6436975 Del Soldato Aug 2002 B1
6441254 Dobert Aug 2002 B1
6448267 Anggard et al. Sep 2002 B1
6451337 Smith et al. Sep 2002 B1
6455542 Anggard et al. Sep 2002 B1
6469065 Garvey et al. Oct 2002 B1
6471978 Stamler et al. Oct 2002 B1
6472390 Stamler et al. Oct 2002 B1
6488951 Toone et al. Dec 2002 B2
6492405 Haj-Yehia Dec 2002 B2
6511991 Hrabie et al. Jan 2003 B2
6514934 Garvey et al. Feb 2003 B1
6538033 Bing Mar 2003 B2
6560478 Alfano et al. May 2003 B1
6562344 Stamler et al. May 2003 B1
6562785 Shapiro May 2003 B1
6583113 Stamler et al. Jun 2003 B2
6583311 Toone et al. Jun 2003 B2
6605447 Weiss et al. Aug 2003 B2
6610660 Saavedra et al. Aug 2003 B1
6627602 Stamler et al. Sep 2003 B2
6642208 Cooke et al. Nov 2003 B2
6642260 Haj-Yehia Nov 2003 B2
6645518 Tedeschi et al. Nov 2003 B2
6646006 Cooke et al. Nov 2003 B2
6656217 Herzog, Jr. et al. Dec 2003 B1
6673338 Arnold et al. Jan 2004 B1
6673891 Stamler et al. Jan 2004 B2
6699846 Elliott et al. Mar 2004 B2
6703046 Fitzhugh et al. Mar 2004 B2
6706274 Hermann et al. Mar 2004 B2
6709681 Benjamin et al. Mar 2004 B2
6723703 Gaston et al. Apr 2004 B2
6737447 Smith et al. May 2004 B1
6747062 Murrell Jun 2004 B2
6750254 Hrabie et al. Jun 2004 B2
6758214 Fine et al. Jul 2004 B2
6759430 Anggard et al. Jul 2004 B2
6780849 Herrmann et al. Aug 2004 B2
6793644 Stenzler Sep 2004 B2
6796966 Thomas Sep 2004 B2
6841166 Zhang et al. Jan 2005 B1
6855366 Smith et al. Feb 2005 B2
6875840 Stamler et al. Apr 2005 B2
6887485 Fitzhugh et al. May 2005 B2
6887994 Stamler et al. May 2005 B2
6894073 Lee et al. May 2005 B2
6896899 Demopolos et al. May 2005 B2
6897218 Casella et al. May 2005 B2
6911433 Saavedra et al. Jun 2005 B2
6911478 Hrabie et al. Jun 2005 B2
6946484 Adams et al. Sep 2005 B2
6949530 Hrabie et al. Sep 2005 B2
6951902 McDonald et al. Oct 2005 B2
6964984 Stamler et al. Nov 2005 B2
6974801 Honda et al. Dec 2005 B2
7012098 Manning et al. Mar 2006 B2
7015347 Toone et al. Mar 2006 B2
7025869 Fine et al. Apr 2006 B2
7030238 Stamler et al. Apr 2006 B2
7033999 Stamler et al. Apr 2006 B2
7040313 Fine et al. May 2006 B2
7048951 Seitz et al. May 2006 B1
7049308 Stamler et al. May 2006 B2
7052711 West et al. May 2006 B2
7070798 Michal et al. Jul 2006 B1
7081524 Saavedra et al. Jul 2006 B2
7087588 Del Soldato Aug 2006 B2
7087709 Stamler et al. Aug 2006 B2
7122018 Stenzler et al. Oct 2006 B2
7122027 Trescony et al. Oct 2006 B2
7122529 Ruane et al. Oct 2006 B2
7128904 Batchelor et al. Oct 2006 B2
7135189 Knapp Nov 2006 B2
7135498 Chopp et al. Nov 2006 B1
7157500 Stamler et al. Jan 2007 B2
7169809 Berthelette et al. Jan 2007 B2
7176237 Honda et al. Feb 2007 B2
7179475 Burnett et al. Feb 2007 B1
7189761 Gorfine Mar 2007 B2
7199154 Berthelette et al. Apr 2007 B2
7204980 Clark Apr 2007 B2
7226586 Fitzhugh et al. Jun 2007 B2
7234079 Cheng Jun 2007 B2
7259250 Stamler et al. Aug 2007 B2
7279176 West et al. Oct 2007 B1
7282519 Garvey et al. Oct 2007 B2
7314857 Madhyastha Jan 2008 B2
7335383 Meyerhoff et al. Feb 2008 B2
7345053 Garvey Mar 2008 B2
7348319 Hrabie et al. Mar 2008 B2
7364585 Weber Apr 2008 B2
7396829 Garvey et al. Jul 2008 B2
7417109 Stamler et al. Aug 2008 B2
7425218 Keefer et al. Sep 2008 B2
7432301 Gaston et al. Oct 2008 B2
7452916 Cooke Nov 2008 B2
7468435 Waterhouse et al. Dec 2008 B2
7485324 Miller et al. Feb 2009 B2
7520866 Stenzler et al. Apr 2009 B2
7531164 Daaka et al. May 2009 B2
7569559 Arnold et al. Aug 2009 B2
7582623 Mascharak Sep 2009 B2
7595313 Garvey et al. Sep 2009 B2
7622501 Dufresne et al. Nov 2009 B2
7622502 Berthelette et al. Nov 2009 B2
7645748 Orchansky et al. Jan 2010 B2
7645749 Orchansky et al. Jan 2010 B2
7651697 West et al. Jan 2010 B2
7655423 Chopp et al. Feb 2010 B2
7678391 Graham et al. Mar 2010 B2
7678830 Honda et al. Mar 2010 B2
7696247 Herrmann et al. Apr 2010 B2
7745656 Toone et al. Jun 2010 B2
7763283 Batchelor et al. Jul 2010 B2
7785616 Stamler et al. Aug 2010 B2
7795286 Lucet-Levannier Sep 2010 B2
7799335 Herrmann et al. Sep 2010 B2
7807716 Farber Oct 2010 B2
7811600 Cheng et al. Oct 2010 B2
7820284 Terry Oct 2010 B2
7829553 Arnold et al. Nov 2010 B2
7838023 Garvey et al. Nov 2010 B2
7846400 Hyde et al. Dec 2010 B2
7862598 Hyde et al. Jan 2011 B2
7892198 Stenzler Feb 2011 B2
7897399 Hyde et al. Mar 2011 B2
7928079 Hrabie et al. Apr 2011 B2
7928096 Waterhouse et al. Apr 2011 B2
7947299 Knapp May 2011 B2
7972137 Rosen Jul 2011 B2
7975699 Hyde et al. Jul 2011 B2
8003811 Almirante Aug 2011 B2
8017074 Arnold Sep 2011 B2
8021679 Chen Sep 2011 B2
8034384 Meyerhoff Oct 2011 B2
8043246 Av-Gay et al. Oct 2011 B2
20010012851 Lundy et al. Aug 2001 A1
20010025057 Gorfine Sep 2001 A1
20010038832 Bonavida et al. Nov 2001 A1
20010053772 Bonavida et al. Dec 2001 A1
20020028851 Bianchi et al. Mar 2002 A1
20020049157 Wu et al. Apr 2002 A1
20020061879 Garvey et al. May 2002 A1
20020068365 Kuhrts Jun 2002 A1
20020090401 Tucker et al. Jul 2002 A1
20020115586 Enikolopov Aug 2002 A1
20020132234 Moskowitz Sep 2002 A1
20020136763 Demopoulos et al. Sep 2002 A1
20020138051 Hole et al. Sep 2002 A1
20020143007 Garvey et al. Oct 2002 A1
20020143062 Lopez-Berestein et al. Oct 2002 A1
20020155174 Benjamin et al. Oct 2002 A1
20020161042 Gorfine Oct 2002 A1
20030027844 Soldato Feb 2003 A1
20030039697 Zhao et al. Feb 2003 A1
20030050305 Tejada Mar 2003 A1
20030072783 Stamler et al. Apr 2003 A1
20030093143 Zhao et al. May 2003 A1
20030134779 Diarra et al. Jul 2003 A1
20030170674 Moskowitz Sep 2003 A1
20030203915 Fang et al. Oct 2003 A1
20030205234 Bardach et al. Nov 2003 A1
20040009238 Miller et al. Jan 2004 A1
20040013747 Tucker et al. Jan 2004 A1
20040033480 Wong Feb 2004 A1
20040037836 Stamler et al. Feb 2004 A1
20040037897 Benjamin et al. Feb 2004 A1
20040043068 Tedeschi et al. Mar 2004 A1
20040076582 Dimatteo et al. Apr 2004 A1
20040082659 Cooke et al. Apr 2004 A1
20040105898 Benjamin et al. Jun 2004 A1
20040110691 Stamler Jun 2004 A1
20040131703 Bach et al. Jul 2004 A1
20040143010 Esteve-Soler et al. Jul 2004 A1
20040147598 Haj-Yehia Jul 2004 A1
20040157936 Burnett et al. Aug 2004 A1
20040228889 Cals-Grierson Nov 2004 A1
20040254419 Wang et al. Dec 2004 A1
20040265244 Rosen Dec 2004 A1
20050036949 Tucker et al. Feb 2005 A1
20050037093 Benjamin Feb 2005 A1
20050054714 Munoz et al. Mar 2005 A1
20050065161 Garvey et al. Mar 2005 A1
20050069595 Chen et al. Mar 2005 A1
20050074506 Natan et al. Apr 2005 A1
20050079132 Wang et al. Apr 2005 A1
20050080021 Tucker et al. Apr 2005 A1
20050080024 Tucker et al. Apr 2005 A1
20050131064 Gaston et al. Jun 2005 A1
20050142217 Adams et al. Jun 2005 A1
20050142218 Tucker et al. Jun 2005 A1
20050152891 Toone et al. Jul 2005 A1
20050165452 Sigg et al. Jul 2005 A1
20050171066 Shami Aug 2005 A1
20050171199 Murrell Aug 2005 A1
20050187222 Garvey et al. Aug 2005 A1
20050220838 Zhao et al. Oct 2005 A1
20050249818 Sawan et al. Nov 2005 A1
20050265958 West et al. Dec 2005 A1
20050281867 Kahn et al. Dec 2005 A1
20060008529 Meyerhoff et al. Jan 2006 A1
20060009431 Earl et al. Jan 2006 A1
20060035854 Goldstein et al. Feb 2006 A1
20060039950 Zhou et al. Feb 2006 A1
20060058363 Wang et al. Mar 2006 A1
20060067909 West et al. Mar 2006 A1
20060095120 Hermann May 2006 A1
20060100159 Stamler et al. May 2006 A1
20060142183 Diarra et al. Jun 2006 A1
20060147553 Miller et al. Jul 2006 A1
20060147904 Wong Jul 2006 A1
20060159726 Shell Jul 2006 A1
20060172018 Fine et al. Aug 2006 A1
20060198831 Stamler et al. Sep 2006 A1
20060211601 Stamler et al. Sep 2006 A1
20060269620 Morris et al. Nov 2006 A1
20060286158 Calvert Murrell et al. Dec 2006 A1
20060286159 Calvert Murrell et al. Dec 2006 A1
20070003538 Madhyastha Jan 2007 A1
20070014686 Arnold et al. Jan 2007 A1
20070014733 O'Donnell et al. Jan 2007 A1
20070014828 Fitzhugh et al. Jan 2007 A1
20070037821 Garvey et al. Feb 2007 A1
20070048344 Yahiaoui et al. Mar 2007 A1
20070053952 Chen et al. Mar 2007 A1
20070053955 Larson et al. Mar 2007 A1
20070053966 Ang et al. Mar 2007 A1
20070059351 Murrell et al. Mar 2007 A1
20070086954 Miller Apr 2007 A1
20070087025 Fitzhugh et al. Apr 2007 A1
20070088345 Larson et al. Apr 2007 A1
20070089739 Fine et al. Apr 2007 A1
20070116785 Miller May 2007 A1
20070129690 Rosenblatt et al. Jun 2007 A1
20070148136 Whitlock Jun 2007 A1
20070154570 Miller et al. Jul 2007 A1
20070166227 Liu et al. Jul 2007 A1
20070172469 Clark Jul 2007 A1
20070191377 Worcel Aug 2007 A1
20070196327 Kalivretenos et al. Aug 2007 A1
20070197543 Esteve-Soler et al. Aug 2007 A1
20070202155 Ang et al. Aug 2007 A1
20070203242 Calton Aug 2007 A1
20070207179 Andersen et al. Sep 2007 A1
20070219208 Kalyanaraman et al. Sep 2007 A1
20070225250 Brown Sep 2007 A1
20070239107 Lundberg et al. Oct 2007 A1
20070243262 Hurley et al. Oct 2007 A1
20070248676 Stamler et al. Oct 2007 A1
20070264225 Cheng et al. Nov 2007 A1
20070270348 Kahn et al. Nov 2007 A1
20070275100 Miller Nov 2007 A1
20080025972 Daaka et al. Jan 2008 A1
20080039521 Yasuda et al. Feb 2008 A1
20080045909 Fossel Feb 2008 A1
20080069848 Peters Mar 2008 A1
20080069863 Peters Mar 2008 A1
20080069905 Peters Mar 2008 A1
20080071206 Peters Mar 2008 A1
20080089956 Da et al. Apr 2008 A1
20080139450 Madhyastha et al. Jun 2008 A1
20080145449 Stamler Jun 2008 A1
20080171021 Bach et al. Jul 2008 A1
20080171351 Smith Jul 2008 A1
20080175881 Ippoliti et al. Jul 2008 A1
20080182797 Nudler et al. Jul 2008 A1
20080193385 Maibach Aug 2008 A1
20080193566 Miller et al. Aug 2008 A1
20080207491 Diarra et al. Aug 2008 A1
20080207713 Wang et al. Aug 2008 A1
20080214646 Knaus et al. Sep 2008 A1
20080226751 Tucker et al. Sep 2008 A1
20080241208 Shanley et al. Oct 2008 A1
20080275093 Garvey et al. Nov 2008 A1
20080280984 Fossel Nov 2008 A1
20080286321 Reneker et al. Nov 2008 A1
20080287861 Stenzler et al. Nov 2008 A1
20080311163 Peters Dec 2008 A1
20080317626 Arnold et al. Dec 2008 A1
20080317679 Tamarkin et al. Dec 2008 A1
20090004298 Gaston et al. Jan 2009 A1
20090010989 Peters Jan 2009 A1
20090018091 Ellis et al. Jan 2009 A1
20090028966 Chen et al. Jan 2009 A1
20090036491 Tucker et al. Feb 2009 A1
20090042819 Ellis et al. Feb 2009 A1
20090048219 Garvey Feb 2009 A1
20090069449 Smith et al. Mar 2009 A1
20090081279 Jezek et al. Mar 2009 A1
20090088411 Renzi et al. Apr 2009 A1
20090093510 Clementi et al. Apr 2009 A1
20090098187 Peters et al. Apr 2009 A1
20090108777 Hyde et al. Apr 2009 A1
20090110612 Hyde et al. Apr 2009 A1
20090110712 Hyde et al. Apr 2009 A1
20090110933 Hyde et al. Apr 2009 A1
20090110958 Hyde et al. Apr 2009 A1
20090112055 Hyde et al. Apr 2009 A1
20090112193 Hyde et al. Apr 2009 A1
20090112197 Hyde et al. Apr 2009 A1
20090118819 Merz et al. May 2009 A1
20090123528 Fossel May 2009 A1
20090131342 Ellis May 2009 A1
20090136410 Smith May 2009 A1
20090137683 Yasuda et al. May 2009 A1
20090143417 Smith et al. Jun 2009 A1
20090148482 Peters Jun 2009 A1
20090186859 Velázquez et al. Jul 2009 A1
20090191284 Conoci et al. Jul 2009 A1
20090196930 Surber et al. Aug 2009 A1
20090197964 Summar et al. Aug 2009 A1
20090203653 Garvey Aug 2009 A1
20090214618 Schoenfisch et al. Aug 2009 A1
20090214624 Smith et al. Aug 2009 A1
20090214674 Barraud et al. Aug 2009 A1
20090215838 Garvey et al. Aug 2009 A1
20090221536 Fossel Sep 2009 A1
20090222088 Chen et al. Sep 2009 A1
20090226504 Peters Sep 2009 A1
20090232863 Cheng et al. Sep 2009 A1
20090232868 Chen et al. Sep 2009 A1
20090255536 Av-Gay et al. Oct 2009 A1
20090263416 Dawson et al. Oct 2009 A1
20090264398 Bauer Oct 2009 A1
20090270509 Arnold et al. Oct 2009 A1
20090287072 Meyerhoff et al. Nov 2009 A1
20090297634 Friedman et al. Dec 2009 A1
20090304815 Cossu et al. Dec 2009 A1
20090317885 Mascharak Dec 2009 A1
20100003338 Hubbell et al. Jan 2010 A1
20100015253 Benjamin Jan 2010 A1
20100016790 Peters Jan 2010 A1
20100021506 Jones Jan 2010 A1
20100040703 Miller et al. Feb 2010 A1
20100062055 Herrmann et al. Mar 2010 A1
20100076162 Ameer et al. Mar 2010 A1
20100086530 Martinov Apr 2010 A1
20100087370 Jain et al. Apr 2010 A1
20100099729 Almirante et al. Apr 2010 A1
20100112033 Ganzarolli De Oliveira et al. May 2010 A1
20100112095 Morris et al. May 2010 A1
20100129474 Benjamin et al. May 2010 A1
20100152683 Lindgren et al. Jun 2010 A1
20100159119 Chen et al. Jun 2010 A1
20100166603 Opie Jul 2010 A1
20100178319 Lindgren et al. Jul 2010 A1
20100184992 Toone et al. Jul 2010 A1
20100196517 Fossel Aug 2010 A1
20100197702 Hellberg et al. Aug 2010 A1
20100197802 Jezek et al. Aug 2010 A1
20100209469 Bezwada Aug 2010 A1
20100221308 Madhyastha et al. Sep 2010 A1
20100233304 Pan Sep 2010 A1
20100239512 Morris et al. Sep 2010 A1
20100247611 Balkus, Jr. et al. Sep 2010 A1
20100247680 Szabo Sep 2010 A1
20100255062 Kalivretenos et al. Oct 2010 A1
20100256755 Chen et al. Oct 2010 A1
20100261930 Honda et al. Oct 2010 A1
20100262238 Chen et al. Oct 2010 A1
20100268149 Av-Gay et al. Oct 2010 A1
20100276284 Meyerhoff et al. Nov 2010 A1
20100280122 Fossel Nov 2010 A1
20100285100 Balkus, Jr. et al. Nov 2010 A1
20100303891 Lee et al. Dec 2010 A1
20100311780 Farber Dec 2010 A1
20100323036 Fine Dec 2010 A1
20100324107 Dos Santos et al. Dec 2010 A1
20100330582 Nakamura Dec 2010 A1
20100331542 Smith Dec 2010 A1
20100331968 Morris et al. Dec 2010 A1
20110008815 Stamler et al. Jan 2011 A1
20110033437 Smith et al. Feb 2011 A1
20110046182 Gilmer et al. Feb 2011 A1
20110059036 Arnold et al. Mar 2011 A1
20110059189 Cisneros Mar 2011 A1
20110065783 O'Donnell et al. Mar 2011 A1
20110070318 Jezek et al. Mar 2011 A1
20110071168 Chopp et al. Mar 2011 A1
20110076313 Av-Gay et al. Mar 2011 A1
20110104240 Jones et al. May 2011 A1
20110106000 Jones et al. May 2011 A1
Foreign Referenced Citations (321)
Number Date Country
0 805 678 Oct 2003 EP
0 746 327 Apr 2004 EP
0 724 436 Jul 2004 EP
1 411 908 May 2005 EP
1 163 528 Nov 2005 EP
1 681 068 Jul 2006 EP
1 690 532 Aug 2006 EP
1 690 554 Aug 2006 EP
1 690 557 Aug 2006 EP
1 690 558 Aug 2006 EP
1 700 611 Sep 2006 EP
1 704 876 Sep 2006 EP
1 704 877 Sep 2006 EP
1 704 879 Sep 2006 EP
1 707 224 Oct 2006 EP
1 728 438 Dec 2006 EP
1 731 176 Dec 2006 EP
1 757 278 Feb 2007 EP
1 764 119 Mar 2007 EP
1 790 335 May 2007 EP
1 861 130 Sep 2008 EP
1 343 547 Apr 2009 EP
1 871 433 Apr 2009 EP
1 161 248 May 2009 EP
1 846 058 Jul 2009 EP
2 233 437 Sep 2010 EP
WO 9507691 Mar 1995 WO
WO 9510267 Apr 1995 WO
WO 9512394 May 1995 WO
WO 9519767 Jul 1995 WO
WO 9522335 Aug 1995 WO
WO 9532715 Dec 1995 WO
WO 9608966 Mar 1996 WO
WO 9613164 May 1996 WO
WO 9614844 May 1996 WO
WO 96015781 May 1996 WO
WO 9615797 May 1996 WO
WO 9627386 Sep 1996 WO
WO 9632118 Oct 1996 WO
WO 9632136 Oct 1996 WO
WO 96033757 Oct 1996 WO
WO 9635416 Nov 1996 WO
WO 9716983 May 1997 WO
WO 9731654 Sep 1997 WO
WO 9734014 Sep 1997 WO
WO 97047254 Dec 1997 WO
WO 9805689 Feb 1998 WO
WO 9806389 Feb 1998 WO
WO 9808482 Mar 1998 WO
WO 9808482 Mar 1998 WO
WO 9808496 Mar 1998 WO
WO 9813358 Apr 1998 WO
WO 9819996 May 1998 WO
WO 9820015 May 1998 WO
WO 9822090 May 1998 WO
WO 9829101 Jul 1998 WO
WO 9842661 Oct 1998 WO
WO 9900070 Jan 1999 WO
WO 9901427 Jan 1999 WO
WO 9918949 Apr 1999 WO
WO 9922729 May 1999 WO
WO 9933823 Jul 1999 WO
WO 9937616 Jul 1999 WO
WO 9944595 Sep 1999 WO
WO 9944595 Sep 1999 WO
WO 9951221 Oct 1999 WO
WO 9967210 Dec 1999 WO
WO 9967296 Dec 1999 WO
WO 0003640 Jan 2000 WO
WO 0006151 Feb 2000 WO
WO 0030658 Jun 2000 WO
WO 0033877 Jun 2000 WO
WO 0056333 Sep 2000 WO
WO 0059304 Oct 2000 WO
WO 0063462 Oct 2000 WO
WO 0076318 Dec 2000 WO
WO 0112067 Feb 2001 WO
WO 0115738 Mar 2001 WO
WO 0115738 Mar 2001 WO
WO 0126702 Apr 2001 WO
WO 0126702 Apr 2001 WO
WO 0145732 Jun 2001 WO
WO 0145732 Jun 2001 WO
WO 0170199 Sep 2001 WO
WO 0185227 Nov 2001 WO
WO 0185227 Nov 2001 WO
WO 0189572 Nov 2001 WO
WO 0217880 Mar 2002 WO
WO 0217880 Mar 2002 WO
WO 02017881 Mar 2002 WO
WO 02017881 Mar 2002 WO
WO 0220026 Mar 2002 WO
WO 0220026 Mar 2002 WO
WO 0232418 Apr 2002 WO
WO 0234705 May 2002 WO
WO 0243786 Jun 2002 WO
WO 0243786 Jun 2002 WO
WO 0247675 Jun 2002 WO
WO 02051353 Jul 2002 WO
WO 02051353 Jul 2002 WO
WO 02056864 Jul 2002 WO
WO 02056864 Jul 2002 WO
WO 02056874 Jul 2002 WO
WO 02056904 Jul 2002 WO
WO 02070496 Sep 2002 WO
WO 02076395 Oct 2002 WO
WO 02076395 Oct 2002 WO
WO 03004097 Jan 2003 WO
WO 03006427 Jan 2003 WO
WO 03015605 Feb 2003 WO
WO 03015605 Feb 2003 WO
WO 03017989 Mar 2003 WO
WO 03026717 Apr 2003 WO
WO 03030659 Apr 2003 WO
WO 03041713 May 2003 WO
WO 03047636 Jun 2003 WO
WO 03047636 Jun 2003 WO
WO 03080039 Oct 2003 WO
WO 03092763 Nov 2003 WO
WO 03095398 Nov 2003 WO
WO 03095398 Nov 2003 WO
WO 2004009066 Jan 2004 WO
WO 2004009253 Jan 2004 WO
WO 2004011421 Feb 2004 WO
WO 2004012874 Feb 2004 WO
WO 2004037798 May 2004 WO
WO 2004039313 May 2004 WO
WO 2004039313 May 2004 WO
WO 2004060283 Jul 2004 WO
WO 2004064767 Aug 2004 WO
WO 2004064767 Aug 2004 WO
WO 2004087212 Oct 2004 WO
WO 2004098538 Nov 2004 WO
WO 2004098538 Nov 2004 WO
WO 2005003032 Jan 2005 WO
WO 2005011575 Feb 2005 WO
WO 2005011575 Feb 2005 WO
WO 2005030118 Apr 2005 WO
WO 2005030118 Apr 2005 WO
WO 2005030135 Apr 2005 WO
WO 2005030135 Apr 2005 WO
WO 2005030147 Apr 2005 WO
WO 2005030147 Apr 2005 WO
WO 2005034860 Apr 2005 WO
WO 2005034860 Apr 2005 WO
WO 2005039664 May 2005 WO
WO 2005039664 May 2005 WO
WO 2005067986 Jul 2005 WO
WO 2005070006 Aug 2005 WO
WO 2005070006 Aug 2005 WO
WO 2005070008 Aug 2005 WO
WO 2005070008 Aug 2005 WO
WO 2005070874 Aug 2005 WO
WO 2005070883 Aug 2005 WO
WO 2005072819 Aug 2005 WO
WO 2005077962 Aug 2005 WO
WO 2005077962 Aug 2005 WO
WO 2005081752 Sep 2005 WO
WO 2005081752 Sep 2005 WO
WO 2005081964 Sep 2005 WO
WO 2005094913 Oct 2005 WO
WO 2005102282 Nov 2005 WO
WO 2005107384 Nov 2005 WO
WO 2005107384 Nov 2005 WO
WO 2005112954 Dec 2005 WO
WO 2005115440 Dec 2005 WO
WO 2005115440 Dec 2005 WO
WO 2005120493 Dec 2005 WO
WO 2006023693 Mar 2006 WO
WO 2006023693 Mar 2006 WO
WO 2006037105 Apr 2006 WO
WO 2006037105 Apr 2006 WO
WO 2006041855 Apr 2006 WO
WO 2006041855 Apr 2006 WO
WO 2006045639 May 2006 WO
WO 2006055542 May 2006 WO
WO 2006055542 May 2006 WO
WO 2006058318 Jun 2006 WO
WO 2006064056 Jun 2006 WO
WO 2006066362 Jun 2006 WO
WO 2006084909 Aug 2006 WO
WO 2006084910 Aug 2006 WO
WO 2006084911 Aug 2006 WO
WO 2006084912 Aug 2006 WO
WO 2006084913 Aug 2006 WO
WO 2006084914 Aug 2006 WO
WO 2006095193 Sep 2006 WO
WO 2006095193 Sep 2006 WO
WO 2006096572 Sep 2006 WO
WO 2006097348 Sep 2006 WO
WO 2006099058 Sep 2006 WO
WO 2006099058 Sep 2006 WO
WO 2006100154 Sep 2006 WO
WO 2006100155 Sep 2006 WO
WO 2006100156 Sep 2006 WO
WO 2006122960 Nov 2006 WO
WO 2006122961 Nov 2006 WO
WO 2006125016 Nov 2006 WO
WO 2006125262 Nov 2006 WO
WO 2006127591 Nov 2006 WO
WO 2006127591 Nov 2006 WO
WO 2006128121 Nov 2006 WO
WO 2006128742 Dec 2006 WO
WO 2006128742 Dec 2006 WO
WO 2006128743 Dec 2006 WO
WO 2006130982 Dec 2006 WO
WO 2007003028 Jan 2007 WO
WO 2007005910 Jan 2007 WO
WO 2007005910 Jan 2007 WO
WO 2007012165 Feb 2007 WO
WO 2007016677 Feb 2007 WO
WO 2007016677 Feb 2007 WO
WO 2007023005 Mar 2007 WO
WO 2007024501 Mar 2007 WO
WO 2007024501 Mar 2007 WO
WO 2007027859 Mar 2007 WO
WO 2007028657 Mar 2007 WO
WO 2007030266 Mar 2007 WO
WO 2007030266 Mar 2007 WO
WO 2007050379 May 2007 WO
WO 2007050379 May 2007 WO
WO 2007053292 May 2007 WO
WO 2007053578 May 2007 WO
WO 2007053578 May 2007 WO
WO 2007054373 May 2007 WO
WO 2007057763 May 2007 WO
WO 2007057763 May 2007 WO
WO 2007059311 May 2007 WO
WO 2007059311 May 2007 WO
WO 2007064895 Jun 2007 WO
WO 2007064895 Jun 2007 WO
WO 2007067477 Jun 2007 WO
WO 2007084533 Jul 2007 WO
WO 2007084533 Jul 2007 WO
WO 2007086884 Aug 2007 WO
WO 2007086884 Aug 2007 WO
WO 2007088050 Aug 2007 WO
WO 2007088050 Aug 2007 WO
WO 2007088123 Aug 2007 WO
WO 2007088123 Aug 2007 WO
WO 2007092284 Aug 2007 WO
WO 2007092284 Aug 2007 WO
WO 2007100910 Sep 2007 WO
WO 2007100910 Sep 2007 WO
WO 2007103190 Sep 2007 WO
WO 2007103190 Sep 2007 WO
WO 2007127725 Nov 2007 WO
WO 2007127725 Nov 2007 WO
WO 2007133922 Nov 2007 WO
WO 2007133922 Nov 2007 WO
WO 2007143185 Dec 2007 WO
WO 2007143185 Dec 2007 WO
WO 2007149437 Dec 2007 WO
WO 2007149520 Dec 2007 WO
WO 2007149520 Dec 2007 WO
WO 2008005313 Jan 2008 WO
WO 2008005313 Jan 2008 WO
WO 2008013633 Jan 2008 WO
WO 2008013633 Jan 2008 WO
WO 2008020218 Feb 2008 WO
WO 2008027203 Mar 2008 WO
WO 2008027203 Mar 2008 WO
WO 2008062160 May 2008 WO
WO 2008071242 Jun 2008 WO
WO 2008088507 Jul 2008 WO
WO 2008088507 Jul 2008 WO
WO 2008095841 Aug 2008 WO
WO 2008095841 Aug 2008 WO
WO 2008098192 Aug 2008 WO
WO 2008098192 Aug 2008 WO
WO 2008100591 Aug 2008 WO
WO 2008100591 Aug 2008 WO
WO 2008112391 Sep 2008 WO
WO 2008112391 Sep 2008 WO
WO 2008116497 Oct 2008 WO
WO 2008116925 Oct 2008 WO
WO 2008130567 Oct 2008 WO
WO 2008141416 Nov 2008 WO
WO 2008150505 Dec 2008 WO
WO 2008157393 Dec 2008 WO
WO 2009014616 Jan 2009 WO
WO 2009014829 Jan 2009 WO
WO 2009014829 Jan 2009 WO
WO 2009019498 Feb 2009 WO
WO 2009019498 Feb 2009 WO
WO 2009019499 Feb 2009 WO
WO 2009026680 Mar 2009 WO
WO 2009036571 Mar 2009 WO
WO 2009049208 Apr 2009 WO
WO 2009064861 May 2009 WO
WO 2009064861 May 2009 WO
WO 2009073643 Jun 2009 WO
WO 2009073643 Jun 2009 WO
WO 2009073940 Jun 2009 WO
WO 2009073940 Jun 2009 WO
WO 2009080795 Jul 2009 WO
WO 2009086470 Jul 2009 WO
WO 2009086470 Jul 2009 WO
WO 2009088433 Jul 2009 WO
WO 2009098113 Aug 2009 WO
WO 2009117182 Sep 2009 WO
WO 2009117182 Sep 2009 WO
WO 2009117183 Sep 2009 WO
WO 2009124379 Oct 2009 WO
WO 2009131931 Oct 2009 WO
WO 2009155689 Dec 2009 WO
WO 2009155690 Dec 2009 WO
WO 2010002450 Jan 2010 WO
WO 2010002450 Jan 2010 WO
WO 2010033242 Mar 2010 WO
WO 2010033242 Mar 2010 WO
WO 2010045465 Apr 2010 WO
WO 2010048724 May 2010 WO
WO 2010080213 Jul 2010 WO
WO 2010080213 Jul 2010 WO
WO 2010096320 Aug 2010 WO
WO 2010096320 Aug 2010 WO
WO 2010114669 Oct 2010 WO
WO 2010120414 Oct 2010 WO
WO 2010151505 Dec 2010 WO
WO 2012118819 Sep 2012 WO
Non-Patent Literature Citations (192)
Entry
Frost et al., Synthesis, characterization, and controlled nitric oxide release from S-nitrosothiol-derivatized fumed silica polymer filler particles, Wiley Periodicals, J. Biomed. Mater. Res. 72A: 409-419, 2005.
Al-Sa'Doni et al., “S-Nitrosothiols as Nitric Oxide-Donors: Chemistry, Biology and Possible Future Therapeutic Applications”, Current Medicinal Chemistry, 2004, 11: 2679-2690.
Al-Sa'Doni et al., “Current Status and Future Possibilities of Nitric Oxide-Donor Drugs: Focus on S-Nitrosothiols”, Mini-Reviews in Medicinal Chemistry, 2005, 5: 247-254.
Albert, Klaus, “NMR investigations of stationary phases”, Journal of Separation Science, 2003, 26: 215-224.
Bainbrigge et al., “The thermal stability of S-nitrosothiols: experimental studies andab initio calculations on model compounds”, Journal of the Chemical Society, Perkin Transactions, 1997, 2: 351-353.
Bartberger et al., “Theory, Spectroscopy, and Crystallographic Analysis of S-Nitrosothiols: Conformational Distribution Dictates Spectroscopic Behavior”, Journal of the American Chemical Society, 2000, 122: 5889-5890.
Bogush et al., “Preparation of Monodisperse Silica Particles: Control of Size and Mass Fraction”, Journal of Non-Crystalline Solids, 1988, 104: 95-106.
Branda et al., “The effect of mixing alkoxides on the Stober particles size”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2007, 299: 252-255.
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 3, “Hydrolysis and Condensation II: Silicates”, pp. 97-234, 1990.
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 4, “Particulate Sols and Gels”, pp. 235-302, 1990.
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 8, “Drying”, pp. 453-514, 1990.
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 9, “Structural Evolution During Consolidation”, pp. 515-616, 1990.
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 10, “Surface Chemistry and Chemical Modification”, pp. 617-674, 1990.
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 13, “Film Formation”, pp. 787-838, 1990.
Brunner et al., “In Vitro Cytotoxicity of Oxide Nanoparticles: Comparison to Asbestos, Silica, and the Effect of Particle Solubility”, Environmental Science and Technology, 2006, 40: 4374-4381.
Butler et al., “Chemistry, Analysis, and Biological Roles of S-Nitrosothiols”, Analytical Biochemistry, 1997, 249: 1-9.
Cassidy et al., “Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice”, Journal Photochemistry and Photobiology B: Biology, 2009, 95(2): 71-80, (Abstract Only).
Charville et al., “Reduced bacterial adhesion to fibrinogen-coated substrates via nitric oxide release”, Biomaterials, 2008, 29(30): 4039-4044.
Coneski et al., “Degradable Nitric Oxide-Releasing Biomaterials via Post-Polymerization Functionalization of Cross-Linked Polyesters”, Biomacromolecules, 2010, 11: 3208-3215.
Coneski et al., “Synthesis of nitric oxide-releasing polyurethanes with S-nitrosothiol-containing hard and soft segments”, Polymer Chemistry, 2011, 2: 906-913.
Cooke, John, “NO and angiogenesis”, Atherosclerosis Supplements, 2003, 4: 53-60.
Crichton et al., “Old Iron, Young Copper: from Mars to Venus”, BioMetals, 2001, 14: 99-112.
De Souza et al., “Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: Implications for the treatment of cutaneous leishmaniasis”, Nitric Oxide, 2006, 15: 209-216.
Deupree et al., “Morphological analysis of the antimicrobial action of nitric oxide on Gram-negative pathogens using atomic force microscopy”, Acta Biomaterialia, 2009, 5:1405-1415.
Dicks et al., “Identification of Cu+ as the effective reagent in nitric oxide formation from S-nitrosothiols (RSNO)”, Journal of the Chemical Society, 1996, 2: 481-487.
Dobmeier et al., “Nitric Oxide-Releasing Xerogel-Based Fiber-Optic pH Sensors”, Analytical Chemistry, 2006, 78: 7461-7466.
Etchenique et al., “Photodelivery of Nitric Oxide from a Nitrosothiol-Derivatized Surface”, Journal of the American Chemical Society, 2000, 122: 3967-3968.
Foster et al., “Photocatalytic disinfection using titanium dioxide: spectrum and mechanism of antimicrobial activity”, Applied Microbiology Biotechnology, 2011, 90(6): 1847-1868.
Frost et al., “Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices”, Biomaterials, 2005, 26(14): 1685-1695.
Garcia et al., “S-Nitroso-N-Acetylcysteine (SNAC) Prevents Myocardial Alterations in Hypercholesterolemic LDL Receptor Knockout Mice by Antiinflammatory Action”, Journal of Cardiovascular Pharmacology and Therapeutics, 2008, 51: 78-85.
Gaslain et al., “One-step preparation of thiol-modified mesoporous silica spheres with various functionalization levels and different pore structures”, Journal of Sol-Gel Science and Technology, 2009, 49: 112-124.
Grossi et al., “A Kinetic Study of S-Nitrosothiol Decomposition”, Chemistry—A European Journal, 2002, 8(2): 380-387.
Hatton et al., “Past, Present, and Future of Periodic Mesoporous Organosilicas—The PMOs”, Accounts of Chemical Research, 2005, 38: 305-312.
Hetrick et al., “Reducing implant-related infections: active release strategies”, Chemical Society Reviews, 2006, 35: 780-789.
Hetrick et al., “Reduced foreign body response at nitric oxide-releasing subcutaneous implants”, Biomaterials, 2007, 28(31): 4571-4580.
Hetrick et al., “Antibacterial nitric oxide-releasing xerogels: Cell viability and parallel plate flow cell adhesion studies”, Biomaterials, 2007, 28(11): 1948-1956.
Hogg, Neil, “Biological Chemistry and Clinical Potential of S-Nitrosothiols”, Free Radical Biology & Medicine, 2000, 28(10): 1478-1486.
Huang et al., “Synthesis of uniform, spherical sub-100 nm silica particles using a conceptual modification of the classic LaMer model”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2010, 360: 175-183.
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2012/026960; mailed Mar. 13, 2014; 6 pages.
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2012/026972; mailed Mar. 13, 2014; 6 pages.
Johnston et al., “Porous functionalised silica particles: a potential platform for biomolecular screening”, Chemical Communications, 2005, p. 848-850.
Johnston et al., “A Mechanism for Forming Large Fluorescent Organo-Silica Particles: Potential Supports for Combinatorial Synthesis”, Chemistry of Materials, 2006, 18: 6163-6169.
Katayama et al., “Design and Evaluation of S-Nitrosylated Human Serum Albumin as a Novel Anticancer Drug”, The Journal of Pharmacology and Experimental Therapeutics, 2008, 325(1): 69-76.
Katsumi et al., “Physicochemical, Tissue Distribution, and Vasodilation Characteristics of Nitrosated Serum Albumin: Delivery of Nitric Oxide In Vivo”, Journal of Pharmaceutical Sciences, 2004, 93(9): 2343-2352.
Katsumi et al., “Development of Polyethylene Glycol-Conjugated Poly-S-Nitrosated Serum Albumin, a Novel S-Nitrosothiol for Prolonged Delivery of Nitric Oxide in the Blood Circulation in Vivo”, The Journal of Pharmacology and Experimental Therapeutics, 2005, 314(3): 1117-1124.
Kim et al., “Effect of electrolyte additives on sol-precipitated nano silica particles”, Ceramics International, 2004, 30: 171-175.
Kim et al., “Size Control of Silica Nanoparticles and Their Surface Treatment for Fabrication of Dental Nanocomposites”, Biomacromolecules, 2007, 8: 215-222.
Langford et al., “Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty”, The Lancet, 1994, 344: 1458-1460.
Laszlo et al., “Attenuation by nitrosothiol NO donors of acute intestinal microvascular dysfunction in the rat”, British Journal of Pharmacology, 1995, 115: 498-502.
Lee et al., “Preparation of Highly Monodispersed Hybrid Silica Spheres Using a One-Step Sol-Gel Reaction in Aqueous Solution”, Langmuir, 2007, 23(22): 10875-10878.
Lin et al., “Structural and Morphological Control of Cationic Surfectant-Templated Mesoporous Silica”, Accounts of Chemical Research, 2002, 35: 927-935.
Lin et al., “Preparation of functionalized tertiary thiols and nitrosothiols”, Tetrahedron, 2006, 62(35): 8410-8418.
Marxer et al., “Preparation of Nitric Oxide (NO)-Releasing Sol-Gels for Biomaterial Application”, Chemistry of Materials, 2003, 15: 4193-4199.
Marxer et al., “Sol-gel derived nitric oxide-releasing oxygen sensors”, Analyst, 2005, 130: 206-212.
Meng et al., “Preparation of Highly Monodisperse Hybrid Silica Nanospheres Using a One-Step Emulsion Reaction in Aqueous Solution”, Langmuir, 2009, 25(14): 7879-7883.
Miller et al., “Functionalized Organosilica Microspheres via a Novel Emulsion-Based Route”, Langmuir, 2005, 21: 9733-9740.
Mocellin et al., “Nitric Oxide, a Double Edged Sword in Cancer Biology: Searching for Therapeutic Opportunities”, Medicinal Research Reviews, 2007, 27: 317-352.
Mosquera et al., “New route for producing crack-free xerogels: Obtaining uniform pore size”, Journal of Non-Crystalline Solids, 2008, 354: 645-650.
Mowery et al., “Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release”, Biomaterials, 2000, 21: 9-21.
Nablo et al., “Sol-Gel Derived Nitric-Oxide Releasing Materials that Reduce Bacterial Adhesion”, Journal of the American Chemical Society, 2001, 123: 9712-9713.
Nablo et al., “Antibacterial properties of nitric oxide-releasing sol-gels”, Journal of Biomedical Materials Research Part A, 2003, 67A: 1276-1283.
Nablo et al., “Poly(vinyl chloride)-Coated Sol-Gels for Studying the Effects of Nitric Oxide Release on Bacterial Adhesion”, Biomacromolecules, 2004, 5: 2034-2041.
Nablo et al., “Inhibition of implant-associated infections via nitric oxide release”, Biomaterials, 2005, 26(34): 6984-6990.
Nablo et al., “Nitric oxide-releasing sol-gels as antibacterial coatings for orthopedic implants”, Biomaterials, 2005, 26: 917-924.
Nakamura et al., “Synthesis and Characterization of Organosilica Nanoparticles Prepared from 3-Mercaptopropyltrimethoxysilane as the Single Silica Source”, The Journal of Physical Chemistry C, 2007, 111: 18892-18898.
Nakamura et al., “One-Pot Synthesis and Characterization of Three Kinds of Thiol-Organosilica Nanoparticles”, Langmuir, 2008, 24: 5099-5108.
Noimark et al., “The role of surfaces in catheter-associated infections”, Chemical Society Reviews, 2009, 38: 3435-3448.
O'Halloran et al., “Metallochaperones, an Intracellular Shuttle Service for Metal Ions”, The Journal of Biological Chemistry, 2000, 275(33): 25057-25060.
Osterholtz et al., “Kinetics of the hydrolysis and condensation of organofunctional alkoxysilanes: a review”, Journal of Adhesion Science and Technology, 1992, 6(1): 127-149.
Page et al., “Antimicrobial surfaces and their potential in reducing the role of the inanimate environment in the incidence of hospital-acquired infections”, Journal Materials Chemistry—The Royal Society of Chemistry, 2009, 19: 3819-3831.
Park et al., “Preparation of silica nanoparticles: determination of the optimal synthesis conditions for small and uniform particles”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2002, 197: 7-17.
Pavlos et al., “Photosensitive precursors to nitric oxide”, Current Topics in Medicinal Chemistry, 2005, 5: 635-645.
Polizzi et al., “Water-Soluble Nitric Oxide-Releasing Gold Nanoparticles”, Langmuir, 2007, 23: 4938-4943.
Privett et al., “Efficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation”, Biofouling, 2010, 26(8): 973-983.
Radomski et al., “S-nitroso-glutathione inhibits platelet activation in vitro and in vivo”, British Journal of Pharmacology, 1992, 107: 745-749.
Rahman et al., “An optimized sol-gel synthesis of stable primary equivalent silica particles”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2007, 294: 102-110.
Ramsay et al., “Systemic effects of S-nitroso-glutathione in the human following intravenous infusion”, British Journal of Clinical Pharmacology, 1995, 40: 101-102.
Rao et al., “Synthesis of flexible silica aerogels using methyltrimethoxysilane (MTMS) precursor”, Journal Colloid Interface Science, 2006, 300: 279-285.
Reynolds et al., “Nitric Oxide-Releasing Hydrophobic Polymers: Preparation, Characterization, and Potential Biomedical Applications”, Free Radical Biology & Medicine, 2004, 37(7): 926-936.
Riccio et al., “Stöber Synthesis of Nitric Oxide-Releasing S-Nitrosothiol-Modified Silica Particles”, Chemistry of Materials, 2011, 23: 1727-1735.
Richardson et al., “Potential therapeutic uses for S-nitrosothiols”, Clinical Science, 2002, 102: 99-105.
Rojas et al., “Polyurethane coating release bioactive antibodies to reduce bacterial adhesion”, Journal of Controlled Release, 2000, 63: 175-189.
Sakka et al., “Formation of sheets and coating films from alkoxide solutions”, Journal Non-Crystalline Solids, 1984, 63(1-2): 223-235.
Scherer, George, “Effect of Shrinkage on the Modulus of Silica Gel”, Journal of Non-Crystalline Solids, 1989, 109: 183-190.
Schmidt, H., “Organically Modified Silicates by the Sol-Gel Process”, Materials Research Society Symposia Proceedings, 1984, 32: 327-335.
Schmidt et al., “Principles of hydrolysis and condensation of alkoxysilanes”, Journal Non-Crystalline Solids, 1984, 63(1-2): 1-11.
Seabra et al., “Polynitrosated Polyesters: Preparation, Characterization, and Potential Use for Topical Nitric Oxide Release”, Biomacromolecules, 2005, 6: 2512-2520.
Seabra et al., “Nitric oxide-releasing vehicles for biomedical applications”, Journal of Materials Chemistry, 2009, 20: 1624-1637.
Seabra et al., “Antibacterial Nitric Oxide-Releasing Polyester for the Coating of Blood-Contacting Artificial Materials”, Artificial Organs, 2010, 34(7): E204-E214.
Shin et al., “Inorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide Delivery Scaffold”, Chemistry of Materials, 2008, 20: 239-249.
Sinha et al., “UV-induced DNA damage and repair: a review”, Photochemical & Photobiological Sciences, 2002, 1: 225-236.
Sortino et al., “Light-controlled nitric oxide delivering molecular assemblies”, Chemical Society Reviews, 2010, 39: 2903-2913.
Stasko et al., “S-Nitrosothiol-Modified Dendrimers as Nitric Oxide Delivery Vehicles”, Biomacromolecules, 2008, 9(3):834-841.
Stein et al., “Hybrid Inorganic-Organic Mesoporous Silicates—Nanoscopic Reactors Coming of Age”, Advanced Materials, 2000, 12(19): 1403-1419.
Stober et al., “Controlled Growth of Monodisperse Silica Spheres in the Micron Size Range”, Journal of Colloid and Interface Science, 1968, 26: 62-69.
Tan et al., “Study of the Effects of Progressive Changes in Alkoxysilane Structure on Sol-Gel Reactivity”, The Journal of Physical Chemistry B, 2006, 110: 22353-22364.
Valko et al., “Metals, Toxicity and Oxidative Stress”, Current Medicinal Chemistry, 2005, 12: 1161-1208.
Van Helden et al., “Preparation and Characterization of Spherical Monodisperse Silica Dispersions in Nonaqueous Solvents”, Journal of Colloid and Interface Science, 1981, 81(2): 354-368.
Varu et al., “Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials”, Vascular & Endovasc Surgery, 2009, 43: 121-131.
Vogel et al., “Fluorescent organosilica micro- and nanoparticles with controllable size”, Journal of Colloid and Interface Science, 2007, 310: 144-150.
Walcarius et al., “Rate of Access to the Binding Sites in Organically Modified Silicates. 3. Effect of Structure and Density of Functional Groups in Mesoporous Solids Obtained by the Co-Condensation Route”, Chemistry of Materials, 2003, 15: 4181-4192.
Walshe et al., “Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically”, Annals of Clinical Biochemistry, 2003, 40: 115-121.
Wang et al., “Nitric Oxide Donors: Chemical Activites and Biological Applications”, Chemical Reviews, 2002, 102: 1091-1134.
Williams et al., “The Chemistry of S-Nitrosothials”, Accounts of Chemical Research, 1999, 32: 869-876.
Williams et al., “A chemist's view of the nitric oxide story”, Organic & Biomolecular Chemistry, 2003, 1: 441-449.
Yoo et al., “Influence of Reaction Parameters on Size and Shape of Silica Nanoparticles”, Journal of Nanoscience and Nanotechnology, 2006, 6: 3343-3346.
Extended European Search Report corresponding to European Patent Application No. 12752627.5: 5 pages (mailed Jul. 2, 2015).
Barbe et al., “Silica Particles: A Novel Drug-Delivery System”, Advanced Materials, 2004, 16(21): 1959-1965.
Dobmeier et al., “Antibacterial Properties of Nitric Oxide-Releasing Sol-Gel Microarrays”, Biomacromolecules, 2004, 5: 2493-2495.
Farias-Eisner et al., “The Chemistry and Tumoricidal Activity of Nitric Oxide/Hydrogen Peroxide and the Implications to Cell Resistance/Susceptibility”, The Journal of Biological Chemistry, 1996, 271(11): 6144-6151.
Pulfer et al., “Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts”, Journal of Biomedical Materials Research, 1997, 37(2): 182-189.
Shin et al., “Nitric Oxide-Releasing Sol-Gel Particle/Polyurethane Glucose Biosensors”, Analytical Chemistry, 2004, 76: 4543-4549.
English Translation of Chinese Office Action Corresponding to Chinese Patent Application No. 201080056580.6; Date of Issue: Feb. 25, 2015 (14 pages).
Huang “The mechanism and technique of Sol-Gel” Chemical Industry Press 1st Edition: 15 pages (2005).
Amadeu et al., “Nitric Oxide Donor Improves Healing if Applied on Inflammatory and Proliferative Disease” Journal of Surgical Research 149: 84-93 (2008).
Ashutosh, K. et al., “Use of nitric oxide inhalationin chronic obstructive pulmonary disease” Thorax 55:109-113 (2000).
Azizzadeh, B. et al., “Nitric Oxide Improve Cisplatin Cytotoxicity in Head and Neck Squamous Cell Carcinoma” Laryngoscope 111:1896-1900 (2001).
Barst, R.J. et al., “Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension” Pulmonary Circulation 2(2):139-147 (2012).
Barraud, N., et al., “Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas aeruginosa” Journal of Bacteriology 188(21):7344-7353 (2006).
Benz S. et al., “Effect of Nitric Oxide in Ischemia/Reperfusion of the Pancreas” Journal of Surgical Research 106(1):46-53, (2002).
Bian K. et al., “Vascular System: Role of Nitric Oxide in Cardiovascular Diseases” The Journal of Clinical Hypertension 10(4):304-310 (2008).
Bloch K.D. et al. “Inhaled NO as a therapeutic agent” Cardiovascular Research 75:339-348 (2007).
Bohl Masters et al., “Effects of nitric oxide releasing vinyl poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice” Wound Repair and Regeneration 10(5): 286-294 (2002).
Bonavida B. et al., “Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases” Nitric Oxide (19) 2:152-157 (2008).
Bonavida B. et al., “Therapeutic potential of nitric oxide in cancer” rug Resistance Updates 9(3):157-73 (2006).
Boykin J.V. et al., “HBO mediates increased nitric oxide production associated with wound healing”, Wound Repair and Regeneration 12(2) (2004).
Boykin Jr. J.V., “Wound Nitric Oxide Bioactivity: A Promising Diagnostic Indicator for Diabetic Foot Ulcer Management”, Journal of Wound, Ostomy & Continence Nursing 37(1):25-32 (2010).
Bruch-Gerharz D. et al., “Nitric Oxide in Human Skin: Current Status and Future Prospects”, Journal of Investigative Dermatology 110:1-7 (1998).
Cals-Grierson M.M. et al., “Nitric oxide function in the skin”, Nitric Oxide 10(4):179-193 (2004).
Carlsson S. et al., “Intravesical Nitric Oxide Delivery for Prevention of Catheter-Associated Urinary Tract Infections” Antimicrobial Agents and Chemotherapy 49(6):2352 (2005).
Coban, A., et al., “The Effect of Nitric Oxide Combined with Fluoroquinolones against Salmonellaenterica Serovar Typhimurium in Vitro,” Mem Inst Oswaldo Cruz, Rio de Janeiro, 98(3):419-423 (2003).
De Groote M.A. et al., “NO Inhibitions: Antimicrobial Properties of Nitric Oxide”, Clinical Infectious Diseases 21 (Supplement 2):S162-S165 (1995).
Fang F., “Mechanisms of Nitric Oxide-related Antimicrobial Activity” Journal of Clinical Investigation 99(12):2818-2825 (1997).
Frederiksen L.J. et al., “Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling” Clinical Cancer Research 13:2199-2206 (2007).
Frost et al., “Controlled Photoinitiated Release of Nitric Oxide from Polymer Films Containing S-Nitroso-N-acetyle-DL-penicillamine Derivatized Fumed Silixa Filler” Journal of the American Chemical Society 2004, 126(5):1348-1349.
Frost et al., “Synthesis, characterization, and controlled nitric oxide release from S-nitrosothiol-derivatized fumed silica polymer filler particles” Journal of Biomedical Research, Part A, 72A:409-419 (2005).
Ghaffari A. et al., “Potential application of gaseous nitric oxide as a topical antimicrobial agent” Nitric Oxide 14(1):21-29 (2006).
Gupta, R., et al., “Bioactive materials for biomedical applications using sol-gel technology,” Biomedical Materials 3:1-15 (2008).
Herman A.G. et al., “Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis” European Heart Journal 26:1945-1955 (2005).
Hetrick E.M. et al., “Bactericidal Efficacy of Nitric Oxide-Releasing Silica Nanoparticles” ACS Nano 2(2):235-246 (2008).
Hetrick et al., “Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles”, Biomaterials 30:2782-2789 (2009).
Hirst D. et al., “Targeting nitric oxide for cancer therapy”, Journal of Pharmacy and Pharmacology 59:3-13 (2007).
Howlin R. et al., “Nitric oxide-mediated dispersal and enhanced antibiotic sensitivity in pseudomonas aeruginosa biofilms from the cystic fibrosis lung”, Archives of Disease in Childhood 96:A45 (2011).
Hrabie et al., “Chemistry of the nitric oxide-releasing diazeniumdiolate (“nitrosohydroxylamine”) functional group and its oxygen-substituted derivatives,” Chemical Reviews 102:1135-1154 (2002).
Huerta S. et al., “Nitric oxide donors: Novel cancer therapeutics (Review)”, International Journal of Oncology 33:909-927 (2008).
International Search Report and Written Opinion Corresponding to International Application No. PCT/US2012/26972; Date of Mailing: Feb. 28, 2012; 11 Pages.
International Search Report and Written Opinion Corresponding to International Application No. PCT/US2012/26960; Date of Mailing: Feb. 28, 2012; 18 Pages.
Iwakir, N. et al., Synthesis of Amphiphillic polysiloxanes and their properties for formation of nano-aggregates, Colloid and Polymer Science 287:577-582 (2009).
Johnson T. A. et al., “Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers”, Nitric Oxide, 2009, 7 Pages.
Jones M.L. et al., “Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices”, Applied Microbiology and Biotechnology 88:401-407 (2010).
Kiziltepe T. et al., “JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells”, Blood 110:709-718 (2007).
Lamas S. et al., “Nitric oxide signaling comes of age: 20 years and thriving”, Cardiovascular Research 75:207-209 (2007).
Liu X. et al., “Nitric Oxide Inhalation Improves Microvascular Flow and Decreases Infarction Size After Myocardial Ischemia and Reperfusion”, Journal of the American College of Cardiology, vol. 50, No. 8 (2007).
Luo J. et al., “Nitric oxide: a newly discovered function on wound healing”, Acta Pharmacologica Sinica 26(3):259-264 (2005).
McElhaney-Feser, G., et al., “Synergy of Nitric Oxide and Azoles against Candida Species In Vitro,” Antimicrobial Agents And Chemotherapy 42(9):2342-2346 (1998).
McGrowder D. et al., “Therapeutic Uses of Nitric Oxide-donating Drugs in the Treatment of Cardiovascular Diseases” International Journal of Pharmacology 2(4): 366-373 (2006).
Napoli C. et al., “Nitric oxide and atherosclerosis: An update”, Nitric Oxide 15(4):265-279 (2006).
Phillips L. et al., “Nitric Oxide Mechanism of Protection in Ischemia and Reperfusion Injury”, Journal of Investigative Surgery 22:46-55 (2009).
Riccio et al., “Nitric oxide-releasing S-nitrosothiol-modified xerogels” Biomaterials 30:4494-4502 (2009).
Robson, MC, “Wound Infection. A Failure of Wound Healing Caused by an Imbalance of Bacteria,” Surgical Clinics of North America 77(3): 637-50 (1997).
Rothrock A.R. et al., “Synthesis of Nitric Oxide-Releasing Gold Nanoparticles”, Journal of American Chemical Society 127:9362-9363 (2005).
Saaral, NY, “The Equilibrium Between Endothelin-1/Nitric Oxide in Acne Vulgaris,” Istanbul Tip Fakultesi Dergisi Cilt, 2008, 71(4).
Saavedra J.E. et al., “Esterase-Sensitive Nitric Oxide Donors of the Diazeniumdiolate Family: In Vitro Antileukemic Activity ”Journal of Medicinal Chemistry 43:261-269 (2000).
Sato et al. “Dynamic Aspect of Reactive Oxygen and Nitric Oxide in Oral Cavity”, J. Clin. Biochem. Nutr. 42:8-13 (2008).
Schäffer M.R. et al., “Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation”, Surgery 121(5):513-519 (1997).
Schairer D.O. et al., “The potential of nitric oxide releasing therapies as antimicrobial agents” Virulence 3(3):271-279 (2012).
Schulz R. et al., “Nitric oxide in myocardial ischemia/reperfusion injury”, Cardiovascular Research 61:402-413 (2004).
Schwentker A. et al., “Nitric oxide and wound repair: role of cytokines?” Nitric Oxide 7(1):1-10 (2002).
Shin et al. “Synthesis of Nitric Oxide-Releasing Silica Nanoparticles” Journal of American Chemical Society 129(15):4612-4619 (2007).
Shin et al. “Supporting Information: Synthesis of Nitric Oxide-Releasing Silica Nanoparticles” Journal of American Chemical Society 129(15):S1-S4 (2007).
Simeone A.M. et al., “N-(4-Hydroxyphenyl) retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells” Carcinogenesis 27(3):568-577 (2006).
Siriussawakul A. et al. “Role of nitric oxide in hepatic ischemia-reperfusion injury”, World Journal of Gastroenterology 16(48): 6079-6086 (2010).
Shi, HP et al., “The role of iNOS in wound healing” Surgery, vol. 130(2):225-229 (2001).
Slowing et al. “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers” Advanced Drug Delivery Reviews 60:1278-1288 (2008).
Stasko, N., et al., “Dendrimers as a Scaffold for Nitric Oxide Release,” J. Am. Chem. Soc., 2006, vol. 128, pp. 8265-8271.
Stevens E.V. et al., “Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth”, Molecular Pharmaceutics 7(3):775-785 (2010).
Summersgill, J., et al., “Killing of Legionella pneumophila by nitric oxide in γ-interferon-activated macrophages,” Journal of Leukocyte Biology 52:625-629 (1992).
Tang, X., et al., “Synthesis of Beta-Lactamase Activated Nitric Oxide Donors,” Biorgania & Medicinal Chemistry Letters 13:1687-1690 (2003).
Terpolilli N.A. et al., “Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles” Circulation Research 110:727-738 (2012).
Thomas D.D. et al., “Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide”, Proceedings of the National Academy of Sciences 101(24):8894-8899 (2004).
Weller R. “Nitric oxide donors and the skin: useful therapeutic agents?” Clinical Science 105:533-535 (2003).
Wink D.A. et al., “The multifaceted roles of nitric oxide in cancer”, Carcinogenesis 19(5):711-721 (1998).
Witte M.B. et al., “Nitric oxide enhances experimental wound healing in diabetes”, British Journal of Surgery 89:1594-1601 (2002).
Witte M.B. et al., “Role of nitric oxide in wound repair”, The American Journal of Surgery 183(4):406-412 (2002).
Yetik-Anacak G. et al., “Nitric oxide and the endothelium: History and impact on cardiovascular disease”, Vascular Pharmacology 45(5):268-276 (2006).
Zhang H. et al., “Nitric Oxide-Releasing Fumed Silica Particles: Synthesis, Characterization, and Biomedical Application”, Journal of the American Chemical Society 125:5015-5024 (2003).
Zhu, D., et al., “Corrosion protection of metals by water-based silane mixtures of bis-[trimethosysilylpropyl]amine and vinyltriacetoxysilane,” Progress in Organic Coatings 49:42-53 (2004).
Zhu H. et al., “Effects of Nitric Oxide on Skin Burn Wound Healing”, Journal of Burn Care & Research 29(5):804-814 (2008).
Zhu H. et al., “Nitric Oxide Accelerates the Recovery from Burn Wounds”, World Journal of Surgery 31: 624-631 (2007).
European Search Report Corresponding to European Patent Application No. 09820905.9; Dated: Feb. 14, 2013; 7 Pages.
Living Water Acid-Alkaline Balance http://www.livingwaterhealthsolutions.com/Articles/alkalize.php Accessed online Nov. 3, 2011.
Salivary pH Testing https://allicincenter.com/pdf/ph—testing.pdf Accessed online Nov. 3, 2011.
Related Publications (1)
Number Date Country
20130344334 A1 Dec 2013 US
Provisional Applications (2)
Number Date Country
61447368 Feb 2011 US
61565694 Dec 2011 US
Continuations (1)
Number Date Country
Parent PCT/US2012/026960 Feb 2012 US
Child 13975930 US